




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C07D 217/26, 241/04, 409/12 A61K 31/47, 31/495		A1	(11) International Publication Number: WO 93/09096 (43) International Publication Date: 13 May 1993 (13.05.93)
(21) International Application Number: PCT/US92/09444 (22) International Filing Date: 3 November 1992 (03.11.92) (30) Priority data: 789,508                      8 November 1991 (08.11.91)    US 883,825                      15 May 1992 (15.05.92)        US (71) Applicant: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors: VACCA, Joseph, P. ; 766 Eisenhower Drive, Telford, PA 18969 (US). DORSEY, Bruce, D. ; 203 Continental Drive, Harleysville, PA 19438 (US). GUARE, James, P. ; 1600 Kumry Road, Quakerstown, PA 18951 (US). HOLLOWAY, M., Katharine ; 171 Forest Trail, Lansdale, PA 19446 (US). HUNGATE, Randall, W. ; 1925 Rampart Lane, Lansdale, PA 19446 (US).			(74) Agent: QUAGLIATO, Carol, S.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: BG, CS, FI, HU, KR, NO, PL, RO, RU. Published With international search report.

(54) Title: HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS



## (57) Abstract

Compounds of formula (I) where R<sup>1</sup> and R<sup>2</sup> are independently hydrogen or optionally-substituted C<sub>1-4</sub>alkyl or aryl, or R<sup>1</sup> and R<sup>2</sup> are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MU	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

- 1 -

10    TITLE OF THE INVENTION  
HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF  
AIDS

15            This application is a continuation-in-part  
of pending U.S. Serial No. 07/789,503, filed November  
8, 1991. This application is related to the  
following cases: U.S. Serial No. 595,913, filed  
October 11, 1990 (Merck Case 18236); U.S. Serial No.  
746,460, filed August 16, 1991 (Merck case 18466);  
20    Merck case 18583, filed October 23, 1991; and Merck  
case 18416.

25            The present invention is concerned with  
compounds which inhibit the protease encoded by human  
immunodeficiency virus (HIV) or pharmaceutically  
acceptable salts thereof and are of value in the  
prevention of infection by HIV, the treatment of  
infection by HIV and the treatment of the resulting  
acquired immune deficiency syndrome (AIDS).  
30    It also relates to pharmaceutical compositions  
containing the compounds and to a method of use of  
the present compounds and other agents for the  
treatment of AIDS and viral infection by HIV.

- 2 -

BACKGROUND OF THE INVENTION

A retrovirus designated human immunodeficiency virus (HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is the extensive post-translational processing of precursor polyproteins by a virally encoded protease to generate mature viral proteins required for virus assembly and function. Inhibition of this processing prevents the production of normally infectious virus. For example, Kohl, N.E. et al., Proc. Nat'l Acad. Sci. 85, 4686 (1988) demonstrated that genetic inactivation of the HIV encoded protease resulted in the production of immature, non-infectious virus particles. These results indicate that inhibition of the HIV protease represents a viable method for the treatment of AIDS and the prevention or treatment of infection by HIV.

The nucleotide sequence of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)]. Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al., Science, 231, 1567 (1986); Pearl, L.H. et al., Nature 329, 351 (1987)]. Applicants demonstrate that the compounds of this invention are inhibitors of HIV protease.

- 3 -

BRIEF DESCRIPTION OF THE INVENTION

Compounds of formula I, as herein defined, are disclosed. These compounds are useful in the inhibition of HIV protease, the prevention of infection by HIV, the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV are also disclosed.

Some abbreviations that may appear in this application are as follows.

ABBREVIATIONS

<u>Designation</u>	<u>Protecting Group</u>
BOC (Boc)	t-butyloxycarbonyl
CBZ (Cbz)	benzyloxycarbonyl(carbo-benzoy)
TBS (TBDMS)	t-butyl-dimethylsilyl
	<u>Activating Group</u>
HBT(HOBT or HOBt)	1-hydroxybenzotriazole hydrate

- 4 -


	<u>Designation</u>	<u>Coupling Reagent</u>
	BOP reagent	benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate
5	BOP-Cl	bis(2-oxo-3-oxazolidinyl)phosphinic chloride
	EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
10		
	(BOC) <sub>2</sub> O (BOC <sub>2</sub> O)	<u>Other</u> di-t-butyl dicarbonate
	n-Bu <sub>4</sub> N <sup>+</sup> F <sup>-</sup>	tetrabutyl ammonium fluoride
15	nBuLi (n-Buli)	n-butyllithium
	DMF	dimethylformamide
	Et <sub>3</sub> N	triethylamine
	EtOAc	ethyl acetate
	TFA	trifluoroacetic acid
20	DMAP	dimethylaminopyridine
	DME	dimethoxyethane
	LDA	lithium diisopropylamide
	THF	tetrahydrofuran
25		<u>Amino Acid</u>
	Ile	L-isoleucine
	Val	L-valine

30

- 5 -

# DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

This invention is concerned with compounds of formula I, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV protease, the prevention or treatment of infection by HIV and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). Compounds of formula I are defined as follows:



wherein

X is -OH or -NH<sub>2</sub>;

Z is -O, -S, or -NH;

R is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>1</sup> and R<sup>2</sup> are independently:

- 1) hydrogen,
- 2) -C<sub>1-4</sub> alkyl unsubstituted or substituted with one or more of
  - a) halo,
  - b) hydroxy,
  - c) C<sub>1-3</sub> alkoxy,
  - d) aryl unsubstituted or substituted with one or more of C<sub>1-4</sub>alkyl, hydroxy or aryl,

- 6 -

- 5
- e) -W-aryl or -W-benzyl,  
wherein W is -O-, -S-, or -NH-,
- f) a 5-7 membered cycloalkyl group  
unsubstituted or substituted with one  
or more of
- 10
- i) halo,  
ii) hydroxy,  
iii) C<sub>1-3</sub> alkoxy, or  
iv) aryl,
- g) heterocycle unsubstituted or  
substituted with one or more of  
hydroxy, C<sub>1-4</sub>alkyl optionally  
substituted with hydroxy, or Boc,
- 15
- h)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- i)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- j)  $\text{-NH-SO}_2\text{C}_{1-3}\text{alkyl}$ ,
- k) -NR<sub>2</sub>,
- 20
- l) -COOR, or
- m) -((CH<sub>2</sub>)<sub>m</sub>O)<sub>n</sub>R wherein m is 2-5 and n is  
zero, 1, 2 or 3, or
- 3) aryl, unsubstituted or substituted with one  
or more of
- 25
- a) halo,  
b) hydroxy,  
c) -NO<sub>2</sub> or -NR<sub>2</sub>,  
d) C<sub>1-4</sub>alkyl,
- 30
- e) C<sub>1-3</sub> alkoxy, unsubstituted or  
substituted with one or more of  
-OH or C<sub>1-3</sub> alkoxy,



- 7 -

- 5
- f)  $-\text{COOR}$ ,
- g)  $-\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{NR}_2$ ,
- h)  $-\text{CH}_2\text{NR}_2$ ,
- i)  $-\text{CH}_2\overset{\text{O}}{\underset{\parallel}{\text{N}}}\text{HCR}$ ,
- j)  $-\text{CN}$ ,
- k)  $-\text{CF}_3$ ,
- 10 l)  $-\overset{\text{O}}{\underset{\parallel}{\text{N}}}\text{HCR}$ ,
- m) aryl  $\text{C}_{1-3}$  alkoxy,
- n) aryl,
- o)  $-\text{NRSO}_2\text{R}$ ,
- p)  $-\text{OP}(\text{O})(\text{OR}_x)_2$ , or
- 15 q)  $-\text{R}^5$ , as defined below; or

$\text{R}^1$  and  $\text{R}^2$  can be joined together to form with the nitrogen to which  $\text{R}^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which consists of the nitrogen to which  $\text{R}^1$  is attached and from 2 to 9 carbon atoms, and is unsubstituted or substituted with

- 1) hydroxy,
- 2)  $\text{C}_{1-4}$  alkyl unsubstituted or substituted with one or more of
- 25 a) halo,
- b) hydroxy,
- c)  $\text{C}_{1-3}$  alkoxy,
- d) aryl,
- 30

- 8 -

- e) a 5-7 membered cycloalkyl group  
unsubstituted or substituted with one  
or more of
- i) halo,
  - ii) hydroxy,
  - iii) C<sub>1-3</sub> alkoxy, or
  - iv) aryl,
- f) heterocycle, or
- g) -NR<sub>2</sub>,
- 3) C<sub>1-3</sub> alkoxy,
- 4)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- 5)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- 6) -NH-SO<sub>2</sub>C<sub>1-3</sub>alkyl,
- 7) heterocycle,
- 8) -W-aryl, or
- 9)  $\text{-W-C(=O)aryl}$ ,
- wherein W is defined above; or

R<sup>1</sup> and R<sup>2</sup> can be joined together to form with the  
nitrogen to which R<sup>1</sup> is attached a 3 to 10 membered  
monocyclic or bicyclic saturated ring system which  
consists of the nitrogen to which R<sup>1</sup> is attached,  
from 1 to 8 carbon atoms and one or more  
unsubstituted or substituted heteroatom selected from

- 1)  $\text{-N-}$   
|  
V-R<sup>1</sup>,

wherein V is absent or  $\text{-C(=O)-}$  or  $\text{-SO}_2\text{-}$ ,

- 9 -

R<sup>1</sup> is defined as above for when R<sup>1</sup> is independent from and not joined to R<sup>2</sup>, and wherein Q is absent or -O-, -NR-, or heterocycle optionally substituted with

5

-C<sub>1-4</sub>alkyl,

2) -N-  
|  
heterocycle,

3) -N-  
|  
C<sub>1-4</sub> alkenyl, unsubstituted or substituted with aryl,

10

4) -N-  
|  
SO<sub>2</sub>-C<sub>1-4</sub>alkenyl, unsubstituted or substituted with aryl,

5) -S(O)<sub>p</sub>-,  
wherein p is zero, 1 or 2, or

15

6) -O-; or

R<sup>1</sup> and R<sup>2</sup> can be joined together to form with the nitrogen to which R<sup>1</sup> is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system, which consists of the nitrogen to which R<sup>1</sup> is attached and from 2 to 9 carbon atoms, in which the saturated ring system is fused to a phenyl ring and the phenyl ring is unsubstituted or substituted with one or more of

20

- 25
- 1) halo,
  - 2) C<sub>1-3</sub> alkoxy,
  - 3) hydroxy,
  - 4) C<sub>1-4</sub> alkyl,
  - 5) -NHR<sup>1</sup>,

30

wherein R<sup>1</sup> is defined as above for when R<sup>1</sup> is independent from and not joined to R<sup>2</sup>, or

6) -NH-heterocycle;

- 10 -

 $R^3$  is

- 1)  $-(CH_2)_r-R^4$ ,  
wherein  $r$  is zero through 5,
- 2)  $C_{1-4}$ alkenyl- $R^4$ , or
- 5 3)  $C_{1-4}$ alkynyl- $R^4$ ;

 $R^4$  is

- 1) hydrogen,
- 2)  $C_{1-4}$  alkyl,
- 10 3)  $C_5-C_{10}$  cycloalkyl, optionally substituted with hydroxy,
- 4)  $C_6-C_{10}$  aryl, unsubstituted or substituted with one or more of
  - a) halo,
  - 15 b) hydroxy,
  - c)  $-NO_2$  or  $-NR_2$ ,
  - d)  $C_{1-4}$ alkyl,
  - e)  $C_{1-3}$  alkoxy, unsubstituted or substituted with one or more of
    - 20  $-OH$  or  $C_{1-3}$  alkoxy,
    - f)  $-COOR$ ,
    - g)  $-C(=O)NR_2$ ,
    - h)  $-CH_2NR_2$ ,
    - 25  $-CH_2NHC(=O)R$ ,
    - i)  $-CN$ ,
    - j)  $-CF_3$ ,
    - k)  $-NH(=O)C(=O)R$ ,
    - 30 l)  $-NH(=O)C(=O)R$ ,
    - m) aryl  $C_{1-3}$  alkoxy,
    - n) aryl,

- 11 -

- o)  $-NRSO_2R$ ,  
 p)  $-OP(O)(OR_x)_2$ , or  
 q)  $-R^5$ , as defined below, or
- 5) monocyclic or bicyclic heterocycle containing  
 5 from 1 to 3 heteroatoms chosen from the  
 group consisting of N, O, and S and which is  
 unsubstituted or substituted with  $R^5$  and  
 optionally with one or more of
- 10 a) halo,  
 b)  $C_{1-4}$  alkyl, or  
 c)  $C_{1-3}$  alkoxy;

$R_x$  is H or aryl;

15  $R^5$  is

- 1)  $-W-(CH_2)_m-NR^6R^7$   
 wherein W is as defined above,  
 m is 2-5, and  
 $R^6$  and  $R^7$  are independently
- 20 a) hydrogen,  
 b)  $C_{1-6}$  alkyl, unsubstituted or  
 substituted with one or more of  
 i)  $C_{1-3}$  alkoxy,  
 ii)  $-OH$ , or  
 25 iii)  $-NR_2$ ,  
 c) the same or different and joined  
 together to form a 5-7 member  
 heterocycle, such as morpholino,  
 containing up to two additional  
 30 heteroatoms selected from
- $$\begin{array}{c} R \\ | \\ -N- \end{array}, \begin{array}{c} O \\ || \\ -S- \end{array}, -O-, -S-, \text{ or } -SO_2-,$$
- the heterocycle optionally substituted with  
 $C_{1-4}$  alkyl, or

- 12 -

d) aromatic heterocycle unsubstituted or substituted with one or more of

i) C<sub>1-4</sub> alkyl, or

ii) -NR<sub>2</sub>,

5 2) -(CH<sub>2</sub>)<sub>q</sub>-NR<sup>6</sup>R<sup>7</sup> wherein q is 1-5, and R<sup>6</sup> and R<sup>7</sup> are defined above, except that R<sup>6</sup> or R<sup>7</sup> are not H or unsubstituted C<sub>1-6</sub> alkyl, or

10 3) benzofuryl, indolyl, azacycloalkyl, azabicyclo C<sub>7-11</sub> cycloalkyl, or benzopiperidinyl, unsubstituted or substituted with C<sub>1-4</sub> alkyl;

15 B is absent, or  $\begin{array}{c} \text{Z} \\ \parallel \\ \text{NH} - \text{C} - \\ | \\ \text{R}^8 \end{array}$ ,

wherein R<sup>8</sup> is

1) -CH(CH<sub>3</sub>)<sub>2</sub>,

2) -CH(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>), or

20 3) -phenyl;

J<sup>1</sup> and J<sup>2</sup> are independently

1) -YR<sup>9</sup> wherein

Y is -O- or -NH-, and

25 R<sup>9</sup> is

a) hydrogen,

b) C<sub>1-6</sub> alkyl, unsubstituted or substituted with one or more of

i) -NR<sub>2</sub>,

30 ii) -OR,

iii) -NHSO<sub>2</sub>C<sub>1-4</sub> alkyl,

- 13 -

- iv)  $-\text{NHSO}_2$  aryl, or  $-\text{NHSO}_2$ (dialkyl-aminoaryl),
- v)  $-\text{CH}_2\text{OR}$ ,
- vi)  $-\text{C}_{1-4}$  alkyl,
- vii)  $-\overset{\text{O}}{\parallel}\text{COR}$ ,
- viii)  $-\overset{\text{O}}{\parallel}\text{CNR}_2$ ,
- ix)  $-\text{NH} \begin{array}{c} \text{NR}_2 \\ \parallel \\ \text{NH} \end{array}$  or  $-\text{NH} \begin{array}{c} \text{NR}_2 \\ \parallel \\ \text{N-CN} \end{array}$ ,
- x)  $-\overset{\text{O}}{\parallel}\text{NHC}^{\text{R}^{13}}$ , wherein  $\text{R}^{13}$  is
- A)  $-\text{H}$ ,
- B)  $-\text{C}_{1-4}$  alkyl,
- C)  $-\text{aryl}$ ,
- D)  $-\text{heterocycle}$ , or
- E)  $-\text{NH}-$ ,  $-\text{O}-$  or  $-(\text{CH}_2)_n-$  wherein  $n$  is zero, 1, 2 or 3, substituted with
- I)  $-\text{C}_{1-4}$  alkyl, unsubstituted or substituted with one or more of aryl or heterocycle, or
- II) aryl, unsubstituted or substituted with heterocycle,
- xi)  $-\text{NR}_3^{\oplus} \text{A}^{\ominus}$  wherein  $\text{A}^{\ominus}$  is a counterion,

- 14 -

xii)  $-\text{NR}^{10}\text{R}^{11}$  wherein  $\text{R}^{10}$  and  $\text{R}^{11}$  are the same or different and are  $\text{C}_{1-5}$  alkyl joined together directly to form a 5-7 membered heterocycle containing up to one additional heteroatom selected from -O-, -S-, or -NR-,

xiii) aryl,

xiv) -CHO,

xv)  $-\text{OP}(\text{O})(\text{OR}_x)_2$ ,

xvi)  $-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{C}_{1-4}\text{alkyl}$  substituted with one or more of amine or quaternary amine, or  $-\text{O}-((\text{CH}_2)_m\text{O})_n-\text{R}$ , or  $-\text{OP}(\text{O})(\text{OR}_x)_2$ ,


xvii)  $-\overset{\text{O}}{\parallel}\text{C}-\text{R}$ , or

xviii)  $-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{CH}_2\text{-heterocycle}$ , or

c)  $-\text{O}-((\text{CH}_2)_m\text{O})_n\text{CH}_3$  or  $-\text{O}-((\text{CH}_2)_m\text{O})_n\text{H}$ , wherein m and n are defined above,

2)  $-\text{N}(\text{R}^9)_2$ ,

3)  $-\text{NR}^{10}\text{R}^{11}$  wherein  $\text{R}^{10}$  and  $\text{R}^{11}$  are defined above, or



wherein Y,  $\text{R}^9$  and n are defined above; and



- 15 -

R<sup>12</sup> is

- 1) hydrogen,
- 2) aryl, unsubstituted or substituted with one or more of

5 a) R<sup>14</sup>, wherein R<sup>14</sup> is

- i) halo,
- ii) -OR,
- iii)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{CNR}_2 \end{array}$ ,
- 10 iv) -CH<sub>2</sub>NR<sub>2</sub>,
- v) -SO<sub>2</sub>NR<sub>2</sub>,
- vi) -NR<sub>2</sub>,
- vii)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{NHCR} \end{array}$ ,
- 15 viii) C<sub>1-4</sub> alkyl,
- ix) phenyl
- x) -CF<sub>3</sub>,
- xi)  $\begin{array}{c} \text{R} \\ | \\ -\text{N}-\text{SO}_2\text{R} \end{array}$ ,
- 20 xii) -OP(O)(OR<sub>x</sub>)<sub>2</sub>, or
- xiii)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{COR} \end{array}$ ,

b) -C<sub>1-4</sub> alkyl-NR<sub>2</sub>, or

25 c)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{O}-\text{C}-\text{C}_{1-4}\text{alkyl} \end{array}$  substituted with one or more of amine or quaternary amine or -OP(O)(OR<sub>x</sub>)<sub>2</sub>,

30

- 16 -

- 3) heterocycle, such as isochroman, chroman, isothiochroman, thiochroman, benzimidazole, benzothiopyran, oxobenzothiopyran, benzopyran, benzothiopyransulfone, benzothiopyransulfoxide, the ring or rings being unsubstituted or substituted with one or more of
- 5 a)  $R^{14}$ , as defined above,  
 b)  $-OC_{1-4}$  alkenyl,  
 10 c) phenyl- $C_{1-4}$  alkyl,  
 d)  $-O-\overset{\overset{O}{\parallel}}{C}-C_{1-4}$  alkyl substituted with one or more of amine or quaternary amine, or  $-OP(O)(OR_x)_2$ , or  
 15  $-O((CH_2)_mO)_n-R$ , or  
 e)  $-O-\overset{\overset{O}{\parallel}}{C}-O-((CH_2)_mO)_n-R$ , or
- 4) A 5 to 7 membered carbocyclic or 7-10 membered bicyclic carbocyclic ring, such as cyclopentane, cyclohexane, indane, norbornane, naphthalene, thiopyran, isothiopyran, or benzopyran, the carbocyclic ring being unsubstituted or substituted with
- 20 one or more of
- a)  $R^{14}$ , as defined above,  
 b)  $-CH_2OR$ ,  
 c)  $-(CH_2)_n-NR_2$ ,  $C_{5-16}$  alkyl, pyridine,  
 25  $-(CH_2)_nNR-(CH_2)_n-NR_2$ ,  $-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-OR$ ,  
 30

- 17 -

$-\text{((CH}_2\text{)}_m\text{O)}_n\text{-R}$ , quinuclidiniumyl  
 substituted with R, piperazine-  
 $\text{C}_{1-4}$ alkyl-benzyl substituted once or  
 more with R, or  
 morpholino- $\text{C}_{1-4}$ alkyl-benzyl,

d)  $-\text{O}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{C}_{1-4}\text{alkyl}$  substituted with  
 one or more of amine or quaternary  
 amine,  $-\text{OP}(\text{O})(\text{OR}_x)_2$ , or  
 $-\text{O}-\text{((CH}_2\text{)}_m\text{O)}_n\text{-R}$ ,

e)  $-\text{O}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{O}-\text{((CH}_2\text{)}_m\text{O)}_n\text{-R}$ , or  
 f)  $-\text{C}_{1-4}\text{alkyl-phenyl}$ ;

or a pharmaceutically acceptable salt thereof.

In a preferred embodiment of this invention,  
 $\text{R}^1$  and  $\text{R}^2$  are joined together to form with the  
 nitrogen to which  $\text{R}^1$  is attached a 3 to 10 membered  
 monocyclic or bicyclic saturated ring system which  
 consists of the nitrogen to which  $\text{R}^1$  is attached and  
 from 2 to 9 carbon atoms, and is unsubstituted or  
 substituted with

1) hydroxy,

2)  $\text{C}_{1-4}$  alkyl unsubstituted or substituted with  
 one or more of

a) hydroxy,

b)  $\text{C}_{1-3}$  alkoxy,

c) aryl,

d) a 5-7 membered cycloalkyl group  
 unsubstituted or substituted with one  
 or more of

- 18 -

- i) halo,
- ii) hydroxy,
- iii) C<sub>1-3</sub> alkoxy, or
- iv) aryl,
- 5 e) heterocycle, or
- f) -NR<sub>2</sub>,
- 3) C<sub>1-3</sub> alkoxy,
- 4)  $\text{-NH-}\overset{\text{O}}{\parallel}\text{COC}_{1-3}\text{alkyl},$
- 10 5)  $\text{-NH-}\overset{\text{O}}{\parallel}\text{C-C}_{1-3}\text{alkyl},$
- 6)  $\text{-NH-SO}_2\text{C}_{1-3}\text{alkyl},$
- 7) -W-aryl, or
- 8)  $\text{-W-}\overset{\text{O}}{\parallel}\text{C-aryl},$
- 15

wherein W is -O-, -S-, or -NH-; or

R<sup>1</sup> and R<sup>2</sup> are joined together to form with the nitrogen to which R<sup>1</sup> is attached a 3 to 10 membered  
 20 monocyclic or bicyclic saturated ring system which consists of the nitrogen to which R<sup>1</sup> is attached, from 1 to 8 carbon atoms and one or more unsubstituted or substituted heteroatom selected from

- 1)  $\text{-N-}\overset{\text{V}}{\underset{\text{V-R}^1}{\mid}},$
- 25

wherein V is absent or  $\text{-}\overset{\text{O}}{\parallel}\text{C-Q-}$  or  $\text{-SO}_2\text{-Q-}$ ,  
 R<sup>1</sup> is defined as above for when R<sup>1</sup> is independent from and not joined to R<sup>2</sup>,  
 30 and wherein Q is absent or -O-, -NR-, or heterocycle optionally substituted with -C<sub>1-4</sub>alkyl,

- 19 -

- 2)  $\begin{array}{c} \text{-N-} \\ | \\ \text{C}_{1-4} \end{array}$  alkenyl, unsubstituted or substituted  
with aryl,
- 3)  $\text{-S(0)}_p\text{-}$ ,  
5                    wherein p is zero, 1 or 2, or
- 4)  $\text{-O-}$ ; or

$\text{R}^1$  and  $\text{R}^2$  are joined together to form with the  
nitrogen to which  $\text{R}^1$  is attached a 3 to 10 membered  
10 monocyclic or bicyclic saturated ring system, which  
consists of the nitrogen to which  $\text{R}^1$  is attached and  
from 2 to 9 carbon atoms, in which the saturated ring  
system is fused to a phenyl ring and the phenyl ring  
is unsubstituted or substituted with one or more of

- 15            1)  $\text{C}_{1-3}$  alkoxy,  
             2) hydroxy,  
             3)  $\text{C}_{1-4}$  alkyl, or  
             4)  $\text{-NHR}^1$ ,

             wherein  $\text{R}^1$  is defined as above for when  $\text{R}^1$   
20            is independent from and not joined to  $\text{R}^2$ .

A second, more preferred embodiment of this  
invention is further limited to compounds where:


- 25     $\text{R}^1$  and  $\text{R}^2$  are joined together to form with the  
nitrogen to which  $\text{R}^1$  is attached a 3 to 10 membered  
monocyclic or bicyclic saturated ring system which  
consists of the nitrogen to which  $\text{R}^1$  is attached and  
from 2 to 9 carbon atoms, and is unsubstituted or  
30    substituted with

- 20 -


- 1) hydroxy,
- 2) C<sub>1-4</sub> alkyl unsubstituted or substituted with one or more of
  - a) hydroxy,
  - 5 b) C<sub>1-3</sub> alkoxy,
  - c) aryl,
  - d) a 5-7 membered cycloalkyl group unsubstituted or substituted with one or more of
    - 10 i) halo,
    - ii) hydroxy,
    - iii) C<sub>1-3</sub> alkoxy, or
    - iv) aryl,
    - e) heterocycle, or
    - 15 f) -NR<sub>2</sub>,
- 3) C<sub>1-3</sub> alkoxy,
- 4)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- 5)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- 20 6)  $\text{-NH-SO}_2\text{C}_{1-3}\text{alkyl}$ ,
- 7) -W-aryl, or
- 8)  $\text{-W-C(=O)aryl}$ ,
- 25 wherein W is -O-, -S-, or -NH-; or

R<sup>1</sup> and R<sup>2</sup> are joined together to form with the nitrogen to which R<sup>1</sup> is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which consists of the nitrogen to which R<sup>1</sup> is attached, from 1 to 8 carbon atoms and one or more unsubstituted or substituted heteroatom selected from

- 21 -









wherein V is absent or  $\overset{\text{O}}{\parallel}\text{-C-Q-}$  or  $\text{-SO}_2\text{-Q-}$ ,  
 $\text{R}^1$  is defined as above for when  $\text{R}^1$  is  
independent from and not joined to  $\text{R}^2$ ,  
and wherein Q is absent or  $\text{-O-}$ ,  $\text{-NR-}$ , or  
heterocycle optionally substituted with  
 $\text{-C}_{1-4}\text{alkyl}$ ,



$\text{R}^3$  is benzyl, unsubstituted or substituted with one  
or more of

- a) hydroxy,
- b)  $\text{-NO}_2$ , or  $\text{-NR}_2$ ,
- c)  $\text{C}_{1-4}\text{alkyl}$ ,
- d)  $\text{C}_{1-3}$  alkoxy, unsubstituted or  
substituted with one or more of  
 $\text{-OH}$  or  $\text{C}_{1-3}$  alkoxy,



- 22 -

and B is absent.

A third, most preferred embodiment of this invention is further limited to compounds where:

5 X is -OH;


Z is -O;

$R^1$  and  $R^2$  are joined together to form with the nitrogen to which  $R^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which  
10 consists of the nitrogen to which  $R^1$  is attached and from 2 to 9 carbon atoms, and is unsubstituted or substituted with -W-aryl or -W-C-aryl; or

$R^1$  and  $R^2$  are joined together to form with the  
15 nitrogen to which  $R^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which consists of the nitrogen to which  $R^1$  is attached, from 1 to 8 carbon atoms and one of  $\begin{array}{c} \text{-N-} \\ | \\ \text{V-R}^1 \end{array}$ ,

20 wherein V is absent or  $\begin{array}{c} \text{O} \\ || \\ \text{-C-Q-} \end{array}$  or  $\text{-SO}_2\text{-Q-}$ ,  $R^1$  is defined as above for when  $R^1$  is independent from and not joined to  $R^2$ , and wherein Q is absent or -O-, -NR- or  
25 heterocycle optionally substituted with  $\text{-C}_{1-4}\text{alkyl}$ ;


$R^3$  is benzyl, unsubstituted or substituted with one or more of (1) hydroxy, (2)  $\text{C}_{1-3}$  alkoxy substituted  
30 with one or more of -OH or (3)






- 23 -

J<sup>1</sup> is -NH-C<sub>1-4</sub>alkyl; and  
J<sup>2</sup> is




The most preferred compounds of this invention are compounds A through H and J, shown below.

Compound A:




30 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide,

- 24 -

Compound B:

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-  
4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-  
butylcarboxamido)-piperazinyl))-pentaneamide,

15

Compound C:


N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-  
morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-  
(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-  
decahydroisoquinoline)yl))-pentaneamide,

30

- 25 -

Compound D:

5




10

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,

15

Compound E:

20




25


N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-hydroxyethoxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinolinyl))-pentaneamide,

30

- 26 -

Compound F:

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-  
carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-  
piperazinyl))-pentaneamide,

Compound G:


N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-  
2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butyl-  
carboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-  
pentaneamide,

- 27 -

Compound H:

5

10




N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzotriopyranyl)-  
2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-carbobenzyl-  
oxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-  
pentaneamide,

Compound J:

20

25



N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-  
4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-  
(t-butylcarboxamido)-piperazinyl))-pentaneamide.

30

Novel compounds of the present invention  
also include but are not limited to the following  
compounds:

- 28 -

- 5 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N'-(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide,
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-2-naphthyloxyprolineamid)yl)-pentaneamide,
- 10 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-1-naphthyloxyprolineamid)yl)-pentaneamide,
- 15 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-amino-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide,
- 20 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-phenylpropionyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,
- 25 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-benzoyl-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,
- 30 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-amino-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,

- 29 -

5 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N'-  
(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide,

10 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N'-  
t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-pentane-  
amide,

15 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N'-  
t-butyl-4(S)-1-naphthyloxy-prolineamid)yl)-pentane-  
amide,

20 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-amino-5-(2-(3(S)-  
N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroiso-  
quinoline)yl)-pentaneamide,

25 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-  
(3-phenylpropionyl)-2(S)-N'-(t-butylcarboxamido)-  
piperazinyl))-pentaneamide,

30 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-  
benzoyl-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-  
pentaneamide,

- 30 -

5 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-  
(3-phenylpropyl)-2(S)-N'-(t-butylcarboxamido))-piper-  
azinyl)-pentaneamide,

10 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-morph-  
olinyloxy)phenyl)methyl)-4(S)-amino-5-(1-(4-  
carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-  
piperazinyl)pentaneamide,

15 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N'-  
(t-butyl)-4(S)-phenoxyprolineamid)yl)-pentaneamide,

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N'-t-butyl-  
4(S)-2-naphthyloxy-prolineamid)yl)-pentaneamide,

20 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(N'-t-butyl-  
4(S)-1-naphthyloxy-prolineamid)yl)-pentaneamide,

25 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-amino-5-(2-(3(S)-N'-(t-  
butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)-  
yl)pentaneamide,

30 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-(3-phenyl-  
propionyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-  
pentaneamid ,



- 31 -

5 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-benzoyl-  
2(S)-N'-(t-butylcarboxamido)-piperazinyl))-  
pentaneamide,

10 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-(3-phenyl-  
propyl)-2(S)-N'-(t-butylcarboxamido))-piperazinyl)-  
pentaneamide,

15 N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
ethoxy)phenyl)methyl)-4(S)-amino-5-(1-(4-carbobenzyl-  
oxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-  
pentaneamide,

20 N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-  
2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N'-(t-butyl)-  
4(S)-phenoxyprolineamid)yl)-pentaneamide,

N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-  
(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-  
2-naphthyloxy-prolineamid)yl)-pentaneamide,

25 N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-  
(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-  
1-naphthyloxy-prolineamid)yl)-pentaneamide,

30 N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-  
(R)-phenylmethyl-4(S)-amino-5-(2-(3(S)-N'-(t-butyl-  
carboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-  
pentaneamide,

- 32 -

5 N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-phenylpropionyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,

10 N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-benzoyl-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,

15 N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2-(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-phenylpropyl)-2(S)-N'-(t-butylcarboxamido))-piperazinyl)-pentaneamide, or

(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-amino-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide.

20 The compounds of the present invention, may have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention.

25 When any variable (e.g., aryl, heterocycle, R, R<sup>1</sup>, R<sup>2</sup>, A<sup>-</sup>, n, Z, etc.) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of  
30 substituents and/or variables are permissible only if such combinations result in stable compounds.

- 33 -

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; and "cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl (Cyh) and cycloheptyl. "Alkenyl" is intended to include hydrocarbon groups of either a straight or branched configuration with one or more carbon-carbon double bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, and the like. "Alkynyl" is intended to include hydrocarbon groups of either a straight or branched configuration with one or more carbon-carbon triple bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, butynyl, pentynyl, and the like. "Halo", as used herein, means fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, maleate, tartrate, hemitartrate, benzene sulfonate, and the like.

As used herein, with exceptions as noted, "aryl" is intended to mean phenyl (Ph) or naphthyl. "Carbocyclic" is intended to mean any stable 5- to 7-membered carbon ring or 7- to 10-membered bicyclic carbon ring any ring of which may be saturated or unsaturated.

- 34 -

The term heterocycle or heterocyclic, as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring system any  
5 ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the  
10 nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the  
15 creation of a stable structure. Examples of such heterocyclic elements include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl,  
20 pyrazolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl,  
25 isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide,  
30 thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same as morpholinyl.

- 35 -

The pharmaceutically-acceptable salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

- 36 -

Schemes I-III for preparing the novel compounds of this invention are presented below. Tables I and II which follow the schemes illustrate the compounds that can be synthesized by Schemes I-III, but Schemes I-III are not limited by the compounds in the tables nor by any particular substituents employed in the schemes for illustrative purposes. The examples specifically illustrate the application of the following schemes to specific compounds.

Amide couplings used to form the compounds of this invention are typically performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester. Typically, solution phase amide coupling are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.

Additional related information on synthetic background is contained in EPO 0337714.

One method for producing formula I compounds is provided by Scheme I. Dihydro-5(S)-(tert-butyldimethylsilyloxymethyl)-3(2H)-furanone (compound 1 below) is prepared by standard methods known in the art from commercially available dihydro-5(S)-(hydroxymethyl)-2(3H)-furanone. After alkylation of compound 1 to form compound 2, the protecting group of lactone 2 is removed with aqueous HF to afford compound 3.

- 37 -

The alcohol group of 3 is activated by conversion into a leaving group such as mesylate, tosylate or trifylate by treating the alcohol with a sulfonyl chloride or sulfonic anhydride, such as trifluoromethanesulfonic anhydride, in the presence of a hindered amine base such as triethylamine, diethyl isopropylamine or 2,6 lutidine, to afford a compound such as compound 4. The leaving group of compound 4 is displaced by an amine 5, such as N'-t-butyl-(4aS,8aS)-(decahydroisoquinoline)-3(S)-carboxamide, in a high boiling solvent such as DMF or xylene to produce a compound such as 6. A trifluoromethanesulfonyloxy group can be displaced by an amine at room temperature in a solvent such as isopropanol by treatment with N,N-diisopropylethylamine.


Compound 6 is hydrolyzed with aqueous lithium or sodium hydroxide and the resultant hydroxy acid 7 is converted into a protected hydroxy acid 8. The hydroxyl group is conveniently protected with a standard silyl protecting group such as t-butyldimethyl silyl or t-butyldiphenyl silyl.

The protected hydroxy-acid 8 is then coupled to the desired R<sup>12</sup> amine to produce compound 9, and the silyl protecting group is removed with fluoride ion to arrive at compound 10.

30.


- 38 -

## SCHEME I





- 39 -

SCHEME I (CONT'D)

A second method for forming products of  
 20 general formula I is shown in Scheme II. In Scheme  
 II, alkylation of 11 is performed by a first step of  
 deprotonation of 11 with *n*-butyllithium or lithium  
 diisopropylamide (LDA) followed by a second step of  
 adding an alkenyl halide (such as allyl bromide) to  
 25 afford 12.

Dihydroxylation of the olefin of 12 with  
 osmium tetroxide and *N*-methylmorpholine-*N*-oxide (NMO)  
 produces a diastereomeric mixture of diols, 13.  
 Selective mesylation of the primary alcohol of 13  
 30 with methanesulfonyl chloride and either  
 triethylamine or pyridine gives a mesylate 14.

- 40 -

Heating mesylate 14 with an amine in a refluxing alcoholic solvent such as methanol or isopropanol which contains an excess of potassium carbonate produces an amino alcohol such as compound 15. The diastereomers can be separated at this step by standard techniques well known to those of skill in the art. Alternatively, the separation can be done after removal of the ketal.

Removal of the ketal in compound 15 is accomplished by treatment with acid in the presence of methanol, or by aqueous acid or by 1N HCl in THF, to form compound 16.


15

20

25

30

- 41 -

SCHEME II

- 42 -


A third method for forming products of general formula I is shown in Scheme III. Protection of the pyrrolidine -NH- group of compound 17 is carried out with BOC-anhydride and dimethylaminopyridine to give the protected compound 18. Alkylation of 18 is performed by a first step of deprotonation of 18 with a strong base such as lithium hexamethyldisilamide (LHMDS) or lithium diisopropylamide (LDA) followed by a second step of adding an alkyl halide (such as benzyl bromide) to afford compound 19.

The TBS protecting and BOC protecting group of 19 are removed by treatment with aqueous HF in acetonitrile to give alcohol 20. Mesylation of the primary alcohol of 20 with methanesulfonyl chloride and either triethylamine or pyridine gives mesylate 21 which is heated with an amine in a refluxing alcoholic solvent such as methanol or isopropanol which contains an excess of potassium carbonate to produce an amino pyrrolidinone such as compound 22. The pyrrolidine -NH- group of 22 is reprotected as a BOC group as before and the resultant compound 23 is hydrolyzed open with a base such as lithium or sodium hydroxide to afford the acid 24. Compound 24 is then coupled to an  $\text{NH}_2\text{R}^{12}$  amine in a standard manner and the BOC is removed with gaseous HCl or trifluoroacetic acid to give the desired product, exemplified by compound 25.


30

- 43 -


## SCHEME III



- 44 -

SCHEME III (CONT'D)

A compound of formula 26




25

wherein P is a nitrogen protecting group such as -BOC or -CBZ, is preferably prepared according to the method described in Scheme I, preferably employing the 5-trifluoromethanesulfonyloxymethyl analog of lactone 4 therein (see Example 15, Step 1).

30


Compounds of formula 27



- 45 -

can be obtained by a variety of routes from compound 28

5



which is obtained after removal of the nitrogen protecting group in 26 using methods well known in the art, e.g., catalytic hydrogenation to remove a CBZ group, or treatment with trimethylsilyltriflate and 2,6 lutidine at about 0°C in a solvent such as CH<sub>2</sub>Cl<sub>2</sub> to remove a BOC group.


For example, the 4-position piperazinyl nitrogen of compound 28 can be alkylated with a compound of formula R<sup>1</sup>-X in a solvent such as DMF in the presence of Et<sub>3</sub>N at room temperature, wherein X is -Cl, Br or -I, or a sulfonamide group can be formed by treatment of 28 with a sulfonyl chloride compound of formula R<sup>1</sup>SO<sub>2</sub>Cl under similar conditions. Also, standard amide coupling techniques can be used to form an amide group at the piperazinyl 4-position. Techniques for these procedures are well known to those skilled in the art. The R<sup>1</sup> group of R<sup>1</sup>-X or R<sup>1</sup>SO<sub>2</sub>Cl is defined above in the definition of compounds of formula I wherein R<sup>1</sup> is independent from and not joined to R<sup>2</sup>, except that R<sup>1</sup> can not be hydrogen or a group with a free hydroxy substituent, such as -C<sub>1-4</sub>alkyl substituted with hydroxy, with the further exception that R<sup>1</sup> can be aryl substituted with a hydroxy group.

The compounds of this invention are also illustrated by Tables I-IV, which follow.

- 46 -

TABLE I

5



10

15

20

25






30

R <sup>3</sup>	X	D
-CH <sub>2</sub> -Ph	-OH	
-CH <sub>2</sub> -Ph	-OH	
-CH <sub>2</sub> -Ph	-OH	
-CH <sub>2</sub> -Ph	-OH	
-CH <sub>2</sub> -Ph	-OH	








- 47 -

TABLE I. CONT'D

	R <sup>3</sup>	X	D
5	-CH <sub>2</sub> -Ph	-OH	
10	-CH <sub>2</sub> -Ph	-OH	
15	-CH <sub>2</sub> -Ph	-OH	
20	-CH <sub>2</sub> -Ph	-OH	
25	-CH <sub>2</sub> -Ph	-OH	
30	-CH <sub>2</sub> -Ph	-OH	





- 48 -

TABLE I. CONT'D

	R <sup>3</sup>	X	D
5	-CH <sub>2</sub> -Ph	-OH	
10	-CH <sub>2</sub> -Ph	-OH	
15			
20	-CH <sub>2</sub> -Ph	-OH	
25	-CH <sub>2</sub> -Ph	-OH	
30	-CH <sub>2</sub> -Ph	-OH	











- 49 -

TABLE I. CONT'D

	<u>R<sup>3</sup></u>	<u>X</u>	<u>D</u>
5			
	-CH <sub>2</sub> -Ph	-OH	
10			
	-CH <sub>2</sub> -Ph	-NH <sub>2</sub>	
15			
	-CH <sub>2</sub> -Ph	-OH	
20			
	-CH <sub>2</sub> -Ph	-OH	
25			
30			

- 50 -

TABLE I. CONT'D

	<u>R<sup>3</sup></u>	<u>X</u>	<u>D</u>
5			
	-CH <sub>2</sub> -Ph	-NH <sub>2</sub>	
10			
	-CH <sub>2</sub> -Ph	-OH	
15			
	-CH <sub>2</sub> -Ph	-OH	
	-CH <sub>2</sub> -Ph	-OH	
20			
	-CH <sub>2</sub> -  -CH <sub>3</sub>	-OH	
25			
	-CH <sub>2</sub> -  -OH	-OH	
30			
	-CH <sub>2</sub> -  -OH	-OH	

- 51 -

TABLE I. CONT'D

	<u>R<sup>3</sup></u>	<u>X</u>	<u>D</u>
5		-NH <sub>2</sub>	
10		-NH <sub>2</sub>	
15		-OH	
20		-OH	
		-NH <sub>2</sub>	
25		-OH	
30		-OH	

- 52 -

TABLE I. CONT'D

	<u>R<sup>3</sup></u>	<u>X</u>	<u>D</u>
5		-NH <sub>2</sub>	
10		-OH	
15		-OH	
20		-OH	
25		-NH <sub>2</sub>	
30		-OH	





- 53 -

TABLE I. CONT'D

	<u>R<sup>3</sup></u>	<u>X</u>	<u>D</u>
5		-OH	
10		-NH <sub>2</sub>	
15		-OH	
20		-OH	
		-NH <sub>2</sub>	
25		-NH <sub>2</sub>	
30		-OH	

- 54 -

TABLE I. CONT'D

5	<u>R<sup>3</sup></u>	<u>X</u>	<u>D</u>
	$-\text{CH}_2\text{CH}=\text{CH}-\text{Ph}$	-OH	
10	$-\text{CH}_2\text{CH}=\text{CH}-\text{Ph}$	-OH	
15	$-\text{CH}_2\text{CH}=\text{CH}-\text{C}_6\text{H}_4-\text{O}-\text{CH}_2\text{CH}_2-\text{N}(\text{CH}_2)_4\text{O}$	-OH	
20	$-\text{CH}_2\text{CH}=\text{CH}-\text{C}_6\text{H}_4-\text{O}-\text{CH}_2\text{CH}_2-\text{N}(\text{CH}_2)_4\text{O}$	-OH	

25


30



- 55 -

TABLE II

5



10

15

A	X	D
	-OH	
	-OH	
	-NH2	









20

25

30















- 56 -

TABLE II Cont'd

	A	X	D
5			
10		-NH <sub>2</sub>	
15		-OH	
20		-OH	
25		-OH	
30			

- 57 -









TABLE II Cont'd

	A	X	D
5		-OH	
10		-NH <sub>2</sub>	
15		-OH	
20		-OH	
25		-OH	
30		-OH	
		-OH	

- 58 -

TABLE II CONT'D

5

A	X	D
	-OH	
	-OH	
	-OH	
	-OH	











25

30

- 60 -





TABLE II. CONT'D

5

	A	X	D
10		-OH	
15		-OH	
20		-OH	
25		-OH	
30		-OH	


- 61 -

TABLE II CONT'D

	A	X	D
5		-OH	
10		-OH	
15			
20			
25			
30			

- 62 -


TABLE III




- 63 -

TABLE IV


5





10



15



20



25



30



- 64 -

The compounds of the present invention are useful in the inhibition of HIV protease the prevention or treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent  
5 pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual  
10 or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or  
15 exposure to patient blood during surgery.

For these purposes, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or  
20 infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.

Thus, in accordance with the present  
25 invention there is further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical  
30 carrier and a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

- 65 -

These pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or  
5 oleagenous suspensions or suppositories.

When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose  
10 for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium  
15 phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.

When administered by nasal aerosol or inhalation, these compositions are prepared according  
20 to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other  
25 solubilizing or dispersing agents known in the art.

The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water,  
30 Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including

- 66 -

synthetic mono- or diglycerides, and fatty acids, including oleic acid.

When rectally administered in the form of suppositories, these compositions may be prepared by  
5 mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.

10 Dosage levels of the order of 0.02 to 5.0 or 10.0 grams-per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two-to-five times higher. For example, infection by HIV is effectively treated by the administration of  
15 from 10 to 50 milligrams of the compound per kilogram of body weight from one to three times per day. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of  
20 factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the  
25 particular condition, and the host undergoing therapy.

The present invention is also directed to combinations of the HIV protease inhibitory compounds with one or more agents useful in the treatment of AIDS. For example, the compounds of this invention may  
30 be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals,

- 67 -

immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.

It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines include in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.

10      Assay for Inhibition of Microbial Expressed  
         Viral Protease

Inhibition studies of the reaction of the protease expressed in *Escherichia coli* with a peptide substrate [Val-Ser-Gln-Asn-(betanaphthyl)Ala-Pro-Ile-Val, 0.5 mg/mL at the time the reaction is initiated] were in 50 mM Na acetate, pH 5.5, at 30°C for 1 hour. Various concentrations of inhibitor in 1.0 ul DMSO were added to 25 ul of the peptide solution in water. The reaction is initiated by the addition of 15 ul of 0.33 nM protease (0.11 ng) in a solution of 0.133 M Na acetate pH 5.5 and 0.1% bovine serum albumin. The reaction was quenched with 160 ul of 5% phosphoric acid. Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C-18 reverse phase, acetonitrile gradient, 0.1% phosphoric acid). The extent of inhibition of the reaction was determined from the peak heights of the products. HPLC of the products, independently synthesized, proved quantitation standards and confirmation of the product composition. The products of synthesis in Examples 1-7 inclusive showed IC<sub>50</sub> values in the range of 1-100 nM. Compounds A, B and J showed IC<sub>50</sub> values of between about 0.3 and about 6 nM.

- 68 -

EXAMPLE 1

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-  
phenylmethyl-4(S)-hydroxy-5-(1-(N'-(t-butyl)-4(S)-  
5 phenoxyprolineamide)yl)-pentaneamide

Step 1: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
3-phenylpropaneamide

To a cold (0°C) solution of methylene  
10 chloride (30 ml) containing 2(R)-hydroxy-1(S)-  
aminoindane (750 mg, 5.0 mmol) and triethylamine (606  
mg, 6.0 mmol) was added a solution of hydrocinnamoyl  
chloride (843 mg, 5.0 mmol) in 5 ml of methylene  
chloride. After 2 hr the reaction was poured into a  
15 separatory funnel containing 50 ml of methylene  
chloride and washed with 10% citric acid solution (2 x  
30 ml). The organic layer was dried, filtered and  
concentrated to afford a white solid.

20 Step 2: Preparation of N-(2(R)-hydroxy-1(S)-indan-  
N.O-isopropylidene-yl)-3-phenyl-propaneamide

The crude white solid from step 1 above was  
dissolved in 50 ml of methylene chloride and 5 ml of  
dimethoxypropane was added followed by the addition of  
25 100 mg of p-toluenesulfonic acid. The reaction was  
stirred at room temperature for 18 hr and then poured  
into a separatory funnel and washed with saturated  
NaHCO<sub>3</sub> solution (2 x 30 ml). The organic layer was  
dried, filtered and concentrated to afford an oil which  
30 was chromatographed (SiO<sub>2</sub>, 40% EtOAc/Hexane) to give an  
oil which eventually crystallized.

- 69 -

Step 3: Preparation of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2(S)-phenylmethyl-pent-4-eneamide

To a solution of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-3-phenyl-propaneamide (1.03 gm, 2.9 mmol) in 20 ml of THF cooled to -78°C was added n-BuLi (2.5M, 1.40 ml, 3.5 mmol). After 20 min, allyl bromide (0.48 gm, 3.9 mmol) was added, the reaction was stirred at -78°C for 1 hr and then 10 ml of saturated NH<sub>4</sub>Cl solution was added to quench the reaction. The reaction was diluted with 50 ml of water, extracted with ethyl acetate (2 x 50 ml), the organic phase was washed with saturated NaCl solution (50 ml), dried filtered and concentrated to afford the crude product. The crude product was purified on silica gel to afford the title compound.

Step 4: Preparation of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2(S)-phenylmethyl-(4(RS).5-dihydroxy)-pentaneamide

To 800 mg (2.2 mmol) of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2(S)-phenylmethyl-pent-4-eneamide dissolved in 40 ml of a 9:1 mixture of acetone/water was added 0.8 ml of a 60% solution of N-methylmorpholine-N-oxide in water followed by 4 ml of a 2.5% solution of osmium tetroxide in t-BuOH. After 18 hr, excess solid sodium bisulfate was added, the reaction was stirred for 2 hr and then filtered through a pad of celite. The filtrate was concentrated, diluted with 50 ml of water, extracted with methylene chloride (2 X 50 ml), the organic phase was dried, filtered and concentrated to give the product as a foam.

- 70 -

Step 5: Preparation of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2(S)-phenylmethyl-4(RS)-hydroxy-5-methanesulfonyloxy-pentaneamide

5 To 200 mg (0.527 mmol) of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2(S)-phenylmethyl-(4(RS),5-dihydroxy)-pentaneamide dissolved in 7 ml of methylene chloride at 0°C was added triethylamine (59 mg, 0.58 mmol), followed by methanesulfonyl chloride  
10 (66 mg, 0.579 mmol). After 4 hr the reaction was worked up by washing with 10% citric acid solution (2 X 50 ml) and the organic phase was dried, filtered and concentrated to afford the monomesylate as a mixture of  
15 alcohols.

Step 6: Preparation of N'-t-butyl-N-Boc-4(R)-hydroxy-L-prolineamide

To a solution of N-Boc-4(R)-hydroxyproline (2.00 g) in DMF (20 mL) cooled to 0°C was added EDC  
20 (1.987 g), HOBt (1.401 g), tert butyl amine (1.09 mL) and triethylamine (2.41 mL). After 18 h the reaction mixture was diluted with ethyl acetate (150 mL) and washed with 10% HCl, saturated NaHCO<sub>3</sub>, water and  
25 brine. The solution was then dried over MgSO<sub>4</sub> and concentrated to afford a white solid.

Step 7: Preparation of N'-t-butyl-N-Boc-4(S)-phenoxy-L-prolineamide

To a solution of N'-t-butyl-N-Boc-4(R)-  
30 hydroxy-L-prolineamide (0.6 g) in THF (5 mL) was added phenol (0.295 g), triphenylphosphine (0.824 g) and then diethylazo-dicarboxylate (0.495 mL) dropwise. The reaction mixture stirred for 24 h at ambient

- 71 -

temperature and was diluted with ethyl acetate (200 mL) and washed with saturated NaHCO<sub>3</sub>, water, brine and dried over MgSO<sub>4</sub>. Concentration in vacuo afforded a yellow oil which was purified by flash chromatography (elution hexane: EtOAc 1:1, 30 mm column).

Step 8: Preparation of N-t-butyl-4(S)-phenoxy-L-prolineamide trifluoroacetic acid salt

To a solution of N'-t-butyl-N-Boc-4(S)-phenoxy-L-prolineamide (0.596 g) in methylene chloride (4 mL) at 0°C was added trifluoroacetic acid (2 mL). After 30 min the reaction was warmed to room temperature and stirred for two hours. The solvent was removed in vacuo and a slightly yellow oil was obtained.

Step 9: Preparation of N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2-(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N'-(t-butyl)-4(S)-phenoxy-prolineamide)yl)-pentaneamide

To a solution of N-t-butyl-4(S)-phenoxy-L-prolineamide trifluoroacetic acid salt (0.36 g) and N-(2(R)-hydroxy-1(S)-indan-N,0-isopropylidene-yl)-2(S)-phenylmethyl-4(RS)-hydroxy-5-methanesulfonyloxy-pentaneamide (0.226 g) in 3 mL of isopropanol was added potassium carbonate (0.441 g) and the reaction was warmed to 80°C. After 18 h the reaction was cooled to room temperature, filtered through celite which was washed with further portions of EtOAc. The filtrate was concentrated, the residue was dissolved in EtOAc (100mL) and washed with water, brine and dried over MgSO<sub>4</sub>. The solvent was removed in vacuo and the resulting oil was purified by flash chromatography to



- 72 -

afford the product as a mixture of diastereomers.

Step 10: Prep of N-(2(R)-hydroxy-1(S)-indanyl)-2-(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-phenoxyprolineamid)yl)-pentaneamide

To a solution of N-(2(R)-hydroxy-1(S)-indan-N,O-isopropylidene-yl)-2-(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(N'-(t-butyl)-4(S)-phenoxyprolineamide)-yl)-pentaneamide (0.13 g) in MeOH (5 mL) was added camphorsulfonic acid (CSA) (0.070 g) at ambient temperature. After 5 hours more CSA (0.025 g) was added and the reaction was stirred for total of 18 hours. The reaction was quenched with saturated NaHCO<sub>3</sub> (5 mL) and the solvent was removed to a volume of 4 mL. The aqueous layer was thoroughly extracted with EtOAc and the organic layer was washed with water, brine and dried. After removal of the solvent *in vacuo* the resulting oil was purified via flash chromatography to provide the title compound as a white foam. The foam was dissolved in EtOAc : hexanes and the mother liquor was decanted away from the oil. The oil was then dried in a high vacuum desiccator to afford a white foam.

25

#### EXAMPLE 2

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-pentaneamide

30

Step 1: Preparation of N-t-butyl-4(S)-2-naphthyloxy-L-prolineamide trifluoroacetic acid salt  
Following substantially the same procedure

- 73 -

for synthesizing N-t-butyl-4(S)-phenoxy-L-proline-  
amide trifluoroacetic acid salt as outlined in Example  
1, Steps 6 through 8, but substituting 2-naphthol for  
the phenol used therein, the 2-naphthyloxy proline  
amide was produced.

Step 2: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N'-  
t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-  
pentaneamide

The title compound was produced by following  
substantially the same procedure outlined in Example 1,  
Steps 9 and 10, but substituting N-t-butyl-4(S)-2-  
naphthyloxy-L-prolineamide trifluoroacetic acid salt  
for the N-t-butyl-4(S)- phenoxy-L-prolineamide  
trifluoroacetic acid salt used in step 9 therein.

### EXAMPLE 3

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-  
phenylmethyl-4(S)-hydroxy-5-(1-(N'-t-butyl-4(S)-1-  
naphthyloxy-prolineamid)yl)-pentaneamide

Step 1: Preparation of N-t-butyl-4(S)-1-naphthyloxy-  
L-prolineamide trifluoroacetic acid salt

Following substantially the same procedure  
for synthesizing N-t-butyl-4(S)-phenoxy-L-proline-  
amide trifluoroacetic acid salt as outlined in Example  
1, Steps 6 through 8, but substituting 1-naphthol for  
the phenol used therein, the 1-naphthyloxy proline  
amide was produced.

- 74 -

Step 2: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(N'-  
t-butyl-4(S)-2-naphthyloxy-prolineamid)yl)-  
pentaneamide

5 The title compound was produced by following  
the procedure outlined in Example 1, Steps 9 and 10,  
but substituting N-t-butyl-4(S)-1-naphthyloxy-L-  
prolineamide trifluoroacetic acid salt for the N-t-  
butyl-4(S)-phenoxy-L-prolineamide trifluoroacetic acid  
10 salt used in Step 9.

EXAMPLE 4

15 Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-  
phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butyl-  
carboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-  
pentaneamide

20 Step 1: Preparation of dihydro-5(S)-((t-butyl-di-  
phenylsilyl)oxymethyl)-3(R)phenylmethyl-  
3(2H)-furanone

25 A solution of lithium diisopropylamide (LDA)  
was generated by the addition 1.55 ml of n-BuLi (2.5M  
in hexane) to 0.55 ml (3.9 mmol) of diisopropylamine  
in 10 ml of THF at -78°C. After 30 minutes a solution  
of dihydro-5-(S)-((t-butyl-diphenylsilyl)-oxymethyl)-  
3(2H)-furanone (1.38 g, 3.89 mmol) in 5 ml of THF was  
added. After an additional 30 minutes of stirring,  
30 benzyl bromide (0.68 g, 3.9 mmol) was added and  
stirring was continued for 3 h after which time the  
reaction was quenched with the addition of a 10%  
aqueous citric acid solution. The solution was

- 75 -

extracted with ethyl acetate (2 x 50 ml) which was backwashed with brine, dried, filtered and concentrated to afford an oil. The product was purified by chromatography (SiO<sub>2</sub>, 20% EtOAc/Hexane) to afford the  
5 title compound.

Step 2: Preparation of dihydro-5(S)-((hydroxymethyl)-3(R)-phenylmethyl-3(2H)-furanone

10 To 5.26 g of dihydro-5(S)-((t-butyldiphenylsilyl)oxymethyl)-3(R)phenylmethyl-3(2H)-furanone in 40 ml of acetonitrile was added 1.34 ml of a 49% aqueous HF solution. After 18 hr at room temperature the reaction was concentrated to dryness and the residue  
15 was partitioned between water (50 ml) and ethyl acetate (50 ml). The organic layer was washed with brine, dried filtered and concentrated to afford the product as a tan solid (mp 69-72°C).

20 Step 3: Preparation of dihydro-5(S)-((methanesulfonyl)oxymethyl)-3(R)phenylmethyl-3(2H)-furanone

To a solution of 2.93 g (14 mmol) of dihydro-5(S)-((hydroxymethyl)-3(R)-phenylmethyl-3(2H)-furanone in methylene chloride cooled to 0°C was added  
25 triethylamine (1.98ml, 15.6 mmol) followed by the addition of methanesulfonyl chloride (1.20 ml, 15.6 mmol). After 1 hour at 0°C, the reaction was poured into 10% aqueous citric acid solution, washed with  
30 ethyl acetate (2 x 100 ml) which was backwashed with water (100 ml), brine (100 ml), dried, filtered and concentrated to give the product as a waxy brown solid.

- 76 -

Step 4: Preparation of dihydro-5(S)-(2-(3(S)-N-(t-butylcarboxamido)-(4aS, 8aS)-(decahydroisoquinoline)yl)methyl)-3(R)-phenylmethyl-3(2H)-furanone

5

To 70 mg of dihydro-5(S)-((methanesulfonyl)-oxymethyl)-3(R)phenylmethyl-3(2H)-furanone (0.25 mmol) in 10 ml of xylene containing 100 mg of potassium carbonate was added 65 mg (0.27 mmol) of N-t-butyl-(4aS,8aS)-(decahydroisoquinoline)-3(S)-carboxamide and the reaction was heated to 140°C. After 6 hours, the reaction was cooled, poured into 30 ml of water which was washed with ethyl acetate (2 x 30 ml). The organic phase was dried, filtered and concentrated to afford a residue which was chromatographed (50/50 EtOAc/Hexane) to give the product.

15

Step 5: Preparation of 2(R)-phenylmethyl-4(S)-(t-butylldimethylsilyloxy)-5-(2-(3(S)-N-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentanoic acid

20

To 130 mg (0.305 mmol) of dihydro-5(S)-(2-(3(S)-N-(t-butylcarboxamido)-(4aS, 8aS)-(decahydroisoquinoline)yl)methyl)-3(R)-phenylmethyl-3-(2H)furanone in 2 ml of DMF was added 1 ml lithium hydroxide solution. After 4 hours at room temperature, the reaction was concentrated to dryness and azeotroped with toluene (3X) to remove excess water. The residue was dissolved in 5 ml of DMF and 414 mg (6.10 mmol) of imidazole and 465 mg (3.05 mmol) of t-butylldimethylsilyl chloride was added. After two days at room

25

30

- 77 -

temperature, 1 ml of methanol was added to the reaction and after 1 hour the solution was evaporated to dryness. The residue was partitioned between saturated  $\text{NH}_4\text{Cl}$  solution (aq) and washed with ethyl acetate which was dried, filtered and concentrated to give an oil which was a mixture of product and the furanone starting material. This material was carried on crude into the next reaction.

10 Step 6: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
2(R)-phenylmethyl-4(S)-(t-butyl dimethyl-  
silyloxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-  
(4aS,8aS)-decahydroisoquinoline)yl)-  
15 pentaneamide

15 The crude product of step 5, above, was dissolved in 3 ml of DMF along with 47 mg (0.246 mmol) of EDC, 33 mg (0.246 mmol) of HOBT and 37 mg of 2(R)-hydroxy-1(S)-aminoindane. The pH of the solution was adjusted to 8.5-9.0 with triethylamine and after 18 hours it was worked up by concentrating to dryness, dissolving the residue in 10% aq. citric acid solution and washing the aqueous layer with ethyl acetate. The organic layer was dried, filtered and concentrated and the resultant oil was chromatographed ( $\text{SiO}_2$ , 30% EtOAc/Hexane) to yield the title compound.

25 Step 7: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-  
30 N'-(t-butylcarboxamido)-(4aS,8aS)-decahydro-  
isoquinoline)yl)-pentaneamide

The product from step 6, above, was dissolved

- 78 -

in 1 ml of THF and 1 ml of a 1M solution of tetrabutylammonium fluoride in THF was added. After 18 hr at room temperature the reaction was diluted with 20 ml of saturated NaHCO<sub>3</sub> solution (aq) and the product  
5 was extracted into ethyl acetate which was dried, filtered and concentrated to give a foam. The resultant material was chromatographed on a prep plate (0.5 mm, 5% MeOH/CHCl<sub>3</sub>) and the title product isolated in the usual manner as a solid with mp 105-107°C.

10

EXAMPLE 5

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-amino-5-(2-(3(S)-N'-(t-butylcarbox-  
15 amido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide

Step 1: Preparation of 5(S)-((t-butyl-dimethyl-silyloxy)methyl)-3(R)-phenylmethyl-N-BOC-2-pyrrolidinone

20 A solution of 5(S)-((t-butyl-dimethyl-silyloxy)methyl)-N-BOC-2-pyrrolidinone (400 mg, 1.26 mmol) in 2 ml of THF was added to a precooled (-78°C) 1M solution of lithium hexamethyldisilazide (1.3 ml) in  
25 5 ml of THF. After 45 min, 0.15 ml of benzyl bromide (1.3 mmol) was added and the stirring was continued. After 5 h the reaction was worked up by pouring into a separatory funnel containing 30 ml of an aqueous 10% citric solution. The aqueous layer was extracted (2 x  
30 30 ml EtOAc) which was backwashed with brine (50 ml) dried, filtered and concentrated to an oil. The residue was chromatographed (SiO<sub>2</sub>, 20% EtOAc/Hexane) to afford the product as an oil.

- 79 -

Step 2: Preparation of 5(S)-hydroxymethyl-3(R)-phenylmethyl-2-pyrrolidinone

To 130 mg (0.34 mmol) of 5(S)-((t-butyl-dimethylsilyloxy)methyl)-3(R)-phenylmethyl-N-BOC-2-pyrrolidinone in 5 ml of acetonitrile was added 0.1 ml of a solution of 48% HF in water. After 3 hr at room temperature the reaction was concentrated to dryness and diluted with 30 ml of an aqueous 10% NaHCO<sub>3</sub> solution. This was extracted with EtOAc (2 X 30 ml), dried filtered and concentrated to afford the crude product.

Step 3: Preparation of 5(S)-(methanesulfonyloxy)-methyl-3(R)-phenylmethyl-2-pyrrolidinone

To a solution of the crude product from Step 2, in 5 ml of methylene chloride cooled to 0°C was added triethylamine (42 mg, 0.41 mmol) and methanesulfonyl chloride (47 mg, 0.41 mmol). The reaction was slowly allowed to warm to room temperature and was stirred for 18 hr after which time it was diluted with 30 ml of methylene chloride, washed with 30 ml of 10% citric acid solution, dried filtered and concentrated to afford the product as an oil.

Step 4: Preparation of 5(S)-(2-(3(S)-N-(t-butylcarboxamido)-(4aS,8aS)-(decahydroisoquinoline)-yl)-methyl)-3(R)-phenylmethyl-2-pyrrolidinone

To a solution of 380 mg (1.34 mmol) of 5(S)-(methanesulfonyloxy)methyl-3(R)-phenylmethyl-2-pyrrolidinone in 20 ml of isopropanol was added 350 mg of potassium carbonate and 360 mg of N-t-butyl-(4aS,8aS)-(decahydroisoquinoline)-3(S)-carboxamide and the reaction was heated to 85°C. After 18 hr the



- 80 -

cooled reaction was filtered through celite, evaporated to dryness and the residue was dissolved in water which was extracted with EtOAc (2 X 50 ml). The organics were dried, filtered and concentrated, and the residue  
5 was chromatographed (SiO<sub>2</sub>, 50/50 EtOAc/Hexane) to afford the product as an oil.

Step 5: Preparation of 5(S)-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-(decahydroisoquinoline)-yl)-methyl)-3(R)-phenylmethyl-N-BOC-2-pyrrolidinone

---

To a solution of the product from step 4, above, (260 mg, 0.611 mmol) in 10 ml of methylene chloride was added dimethylaminopyridine (74 mg, 0.6  
15 mmol) and 133 mg (0.61 mmol) of BOC-anhydride. After 18 hr at room temperature the reaction was worked up by diluting with 30 ml of methylene chloride and the organics washed with 30 ml of 10% citric acid solution, brine (30 ml) dried, filtered and concentrated to  
20 afford an oil. Chromatography (SiO<sub>2</sub>, 40% EtOAc/Hexane) gave the title compound.

Step 6: Preparation of 5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)-yl)-4(S)-[(1',1')-(dimethylethoxycarbonyl)-amino]-2(R)-phenylmethyl-pentanoic acid

---

To a solution of the product of step 5, above, (260 mg, 0.495 mmol) dissolved in 3 ml of dimethoxyethane was added 1.5 ml of a 1M solution of  
30 aqueous lithium hydroxide (1.5 mmol). The reaction was worked up after 2 hr by concentrating to dryness, dissolving the residue in saturated aqueous ammonium chloride solution and the aqueous phase was washed with

- 81 -

ethyl acetate (2 x 50 ml) which was dried, filtered and concentrated to afford the crude acid.

5     Step 7:     Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
                  2(R)-phenylmethyl-4(S)-[(1',1')-(dimethyl-  
                  ethoxycarbonyl)amino]-5-(2-(3(S)-N'-(t-butyl-  
                  carboxamido)-(4aS,8aS)-decahydroisoquinol-  
                  ine)yl)-pentaneamide

10            To a solution of the product of step 6,  
              above, (260 mg, 0.49 mmol) in methylene chloride was  
              added EDC (94 mg, 0.49 mmol), HOBT (66 mg, 0.49 mmol),  
              2(R)-hydroxy-1(S)-aminoindane (73 mg, 0.49 mmol) and  
              the pH of the reaction was adjusted to 8.5-9.0 using  
15            triethylamine. After 5 hr at room temperature the  
              reaction was worked up by diluting with 50 ml of  
              methylene chloride and washing the organics with  
              saturated aqueous ammonium chloride solution. The  
              organic phase was dried, filtered and concentrated and  
20            the residue was chromatographed to afford the title  
              compound as a foam.

25     Step 8:     Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
                  2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-  
                  N'-(t-butylcarboxamido)-(4aS,8aS)-decahydro-  
                  isoquinoline)yl)-pentaneamide

30            To a solution of the product of step 7,  
              above, (180 mg, 0.28 mmol) in 5 ml of methylene  
              chloride cooled to 0°C was added 1 ml of trifluoro-  
              acetic acid. After 4 hr the reaction was worked up by  
              concentrating to dryness and the residue was dissolved  
              in 50 ml of methylene chloride and washed with 10%  
              aqueous NaHCO<sub>3</sub> solution. The organic layer was dried,  
              filtered and concentrated to give the product as a

- 82 -

solid which was chromatographed (SiO<sub>2</sub>, 7% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound, mp = 92-95°C.

#### EXAMPLE 6

5

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2-(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide

Employing substantially the same procedure used in Example 1, but substituting N-t-butyl-4-CBZ-piperazine-2(S)-carboxamide for N-t-butyl-4(S)-phenoxy-L-prolineamide used in step 9 therein, the title compound was obtained.

15

#### EXAMPLE 7

Preparation of N'-(N-(2-pyridyl)-valyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-(N'-t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)pentaneamide

Employing substantially the same procedure used in Example 4, but substituting N-2-pyridyl-valine for the 2(R)-hydroxy-1(S)aminoindane used in step 6 therein, the title compound was obtained.

25

#### EXAMPLE 8

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2(S)-(N'-t-butyl-3-phenyl-propionamide)amino)-pentaneamide

Employing substantially the same procedure used in Example 1, but substituting N-t-butyl-phenyl-alanine amide for the N'-t-butyl-4(S)-phenoxy-

- 83 -

L-prolineamide used in step 9 therein, the title compound is obtained.

#### EXAMPLE 9

5

Preparation of N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydro-isoquinoline)yl)-pentaneamide

10

Step 1: Preparation of N-(4(S)-3,4-dihydro-1H-benzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide

15

Employing substantially the same procedure used in Example 4 but substituting 4(S)-amino-3,4-dihydro-1H-benzothiopyran for the 2(R)-hydroxy-1(S)-aminoindane used in step 6 therein, the title compound is obtained.

20

Step 2: Preparation of N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide

25

The compound from step 1 above is dissolved in a 1:1 mixture of methanol and water. To this is added 10 eq. of OXONE and the reaction is stirred at room temperature. When the reaction is complete, it is concentrated to dryness, water is added and extracted with ethyl acetate which is dried, filtered and concentrated to give the title compound.

30

- 84 -

EXAMPLE 10

Preparation of N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzo-  
thiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-  
5 (4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-  
piperazinyl))-pentaneamide

Step 1: Preparation of dihydro-5(S)-(1-(4-carbo-  
benzyloxy-2(S)-N'-(t-butylcarboxamido)-  
10 piperazinyl)methyl)-3(R)-phenylmethyl-3(2H)-  
furanone

Employing substantially the same procedure  
used in Example 4, step 4 but substituting 4-  
carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piper-  
15 azine for the N'-t-butyl-(4aS,8aS)-(decahydroisoquino-  
line)-3(S)-carboxamide used therein, the title compound  
is produced.

Step 2: Preparation of 2(R)-phenylmethyl-4(S)-  
20 (t-butyldimethylsilyloxy)-5-(1-(4-carbo-  
benzyloxy-2(S)-N'-(t-butylcarboxamido)-  
piperazinyl))-pentanoic acid

Employing substantially the same procedure  
used in Example 4, step 5 but substituting dihydro-  
25 5(S)-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarbox-  
amido)-piperazinyl)methyl)-3(R)-phenylmethyl-3(2H)-  
furanone for the dihydro-5(S)-(2-(3(S)-N'-(t-butyl-  
carboxamido)-(4aS,8aS)-(decahydroisoquinoline)yl)-  
methyl)-3(R)-phenylmethyl-3(2H) furanone used therein,  
30 the title compound is produced.

- 85 -

Step 3: Preparation of N-(4(S)-3,4-dihydro-1H-benzothiopyranyl)-2(R)-phenylmethyl-4(S)-(t-butyldimethylsilyloxy)-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide

5  
The crude 2(R)-phenylmethyl-4(S)-(t-butyldimethylsilyloxy)-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentanoic acid is dissolved in 3ml of DMF along with 1 eq of EDC, 1 eq of HOBT and 1 eq of 4(S)-amino-3,4-dihydro-1H-benzothiopyran. The pH of the solution is adjusted to 8.5-9.0 with triethylamine and after 18 hours it is worked up by concentrating to dryness, dissolving the residue in 10% aq citric acid solution and washing the aqueous layer with ethyl acetate. The organic layer is dried, filtered and concentrated and the resultant residue is chromatographed to yield the title product.

Step 4: Preparation of N-(4(S)-3,4-dihydro-1H-benzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-(t-butylcarboxamido)-piperazinyl))-pentaneamide

20  
The product from step 3 above is dissolved in 1 ml of THF and 1 ml of a 1M solution of tetrabutylammonium fluoride in THF is added. After 18 hr at room temperature the reaction is diluted with 20 ml of saturated NaHCO<sub>3</sub> solution (aq) and the product is extracted into ethyl acetate which is dried, filtered and concentrated to give a residue. The residue is chromatographed to afford the product.

- 86 -

Step 5: Preparation of N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentane-  
amide

5

The compound from step 4 above is dissolved in a 1:1 mixture of methanol and water. To this is added 10 eq of OXONE and the reaction is stirred at room temperature. When the reaction is complete, it is concentrated to dryness, water is added and extracted with ethyl acetate which is dried, filtered and concentrated to give the title compound.

10

EXAMPLE 11

15

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)pentaneamide

20

Step 1: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-allyloxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide

25

To a solution of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-hydroxyphenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide in dioxane is added 6 eq of allyl bromide and 6 eq of cesium carbonate. The reaction is heated to 90°C. When the reaction is complete, the precipitate is filtered off, the dioxane is concentrated to dryness and the residue is diluted with

30

- 87 -

water which is washed with ethyl acetate. The organic phase is dried, filtered and concentrated to afford the product.

5     Step 2:     Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-  
                  2(R)-((4-((2-hydroxy)ethoxy)phenyl)methyl)-  
                  4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarbox-  
                  amido)-(4aS,8aS)-decahydroisoquinoline)yl)-  
                  pentaneamide

10               The product from step 1 above is dissolved  
                  in methanol, 1 eq of p-toluenesulfonic acid is added  
                  and the reaction is cooled to -78°C. Excess ozone is  
                  bubbled through the reaction until a blue color  
                  persists. The flask is purged with nitrogen to remove  
15               any ozone and excess sodium borohydride solution is  
                  added. The reaction is warmed to room temperature and  
                  then saturated NaHCO<sub>3</sub> solution is added. The methanol  
                  is concentrated off on the rotoevaporator and the  
                  aqueous residue is washed with ethyl acetate which is  
20               dried, filtered and concentrated to afford the title  
                  compound.

#### EXAMPLE 12

25     Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-  
                  ((4-((2-hydroxy)ethoxy)phenyl)methyl)-4(S)-hydroxy-  
                  5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-  
                  piperazinyl))-pentaneamide

30               Employing substantially the same procedure  
                  used in Example 11 but substituting N-(2(R)-hydroxy-  
                  1(S)-indanyl)-2(R)-((4-hydroxyphenyl)methyl)-4(S)-  
                  hydroxy-5-(1-(4-carbobenzyloxy-2(S)-(t-butylcarbox-



- 88 -

amido)-piperazinyl)-pentaneamide for the N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-hydroxyphenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide used therein, the  
5 title compound is obtained.

### EXAMPLE 13

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-  
10 ((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide

To a solution of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-hydroxyphenyl)methyl)-4(S)-hydroxy-  
15 5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide in dioxane is added 6 eq of chloroethyl morpholine and 5 eq of cesium carbonate. The reaction is heated to 90°C. When the reaction is complete, the precipitate is filtered off,  
20 the dioxane is concentrated to dryness and the residue is diluted with water which is washed with ethyl acetate. The organic phase is dried, filtered and concentrated to afford the title compound.

25

### EXAMPLE 14

Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-  
((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butyl-  
30 carboxamido)-piperazinyl))-pentaneamide

To a solution of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-hydroxyphenyl)methyl)-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-

- 89 -

5 piperaziny1)-pentaneamide in dioxane is added 6 eq of chloroethyl morpholine and 6 eq of cesium carbonate. The reaction is heated to 90°C. When the reaction is complete, the precipitate is filtered off, the dioxane is concentrated to dryness and the residue is diluted with water which is washed with ethyl acetate. The organic phase is dried, filtered and concentrated to afford the title compound.

10

EXAMPLE 15

15 Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperaziny1))-pentaneamide

15

Step 1: Preparation of dihydro-5(S)-((trifluoromethanesulfonyl)oxymethyl)-3(R)-phenylmethyl-3(2H)-furanone

20 To a solution of 18.4g (89.2 mmol) of dihydro-5(S)-(hydroxymethyl)-3(R)-phenylmethyl-3(2H)-furanone in 350 mL of methylene chloride cooled to 0°C was added 13.51 mL 2,6-lutidine (115.98 mmol) followed by a dropwise addition of 16.51 mL of trifluoromethanesulfonic anhydride (98.1 mmol). After 1.5 hours at 25 0°C, the reaction was poured into a mixture of 300 mL ice/brine and stirred for 0.5 hours. The aqueous layer was then extracted with methylene chloride (3 x 150 mL), the organic layers were washed with 10% HCl (2 x 75 mL), saturated NaHCO<sub>3</sub> (100mL), water (100mL), dried 30 over MgSO<sub>4</sub>, filtered and concentrated to give a solid residue. Purification via flash column chromatography (120 x 150 mm column, gradient elution of hexanes:EtOAc, 4:1 to 3:1) afforded the title product; mp 53-54°C.

- 90 -

**Step 2:** Preparation of 4-(1,1-dimethylethyl)-1-(phenylmethyl)-1,2(S),4-piperazinetricarboxylate

5 The title compound was prepared following the procedure of Bigge, C.F.; Hays, S.J.; Novak, P.M.; Drummond, J.T.; Johnson, G.; Bobovski, T.P. Tetrahedron Lett. 1989, 30, 5193; starting with 2(S)-piperazine-carboxylic acid. (see Felder, E.; Maffei, S.; Pietra, S.; Pitre, D.; Helv. Chim. Acta 1960, 117, 888.

10

**Step 3:** Preparation of N-t-butyl-4-(1,1-dimethylethoxycarbonylamino)-1-(phenylmethylcarbonylamino)piperazine-2(S)-carboxamide

15 To 9.90g (27.16 mmol) of 4-(1,1-dimethylethyl)-1-(phenylmethyl)-1,2(S),4-piperazinetricarboxylate dissolved in 75 mL of DMF and cooled to 0°C was added 5.73g (29.88 mmol) of EDC, 4.03g (29.88 mmol) of HOBt, 3.14 mL (29.88 mmol) of t-butylamine, and finally 4.16 mL (29.88 mmol) of triethylamine. The reaction  
20 mixture was stirred for 18 hours and the reaction volume was concentrated by half. The mixture was then diluted with 600 mL of EtOAc and washed with 10% HCl (2 x 75 mL), saturated NaHCO<sub>3</sub> (1 x 75 mL), water (3 x 75 mL) and brine (1 x 50 mL), dried over MgSO<sub>4</sub> and  
25 concentrated to a solid. This solid was triturated with EtOAc: hexane (1:2) and filtered to provide the title product as a white solid;  
mp 134-135°C.

30

- 91 -

Step 4: Preparation of N-t-butyl-4-(1,1-dimethyl-ethoxycarbonylamino)piperazine-2(S)-carboxamide

To 1.20g (2.86 mmol) of N-t-butyl-4-(1,1-dimethylethoxycarbonylamino)-1-(phenylmethylcarbonylamino)piperazine-2(S)-carboxamide and 1.1g (0.086 mmol) of 10% Pd/C was added 15 mL of methanol. The vessel was charged with hydrogen and the reaction stirred for 2 hours, filtered through celite and washed with ethanol. The solvents were removed in vacuo to provide the title product as a foam.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.65 (br, 1H), 4.10 (m, 1H), 3.81 (br, 1H), 3.21 (dd, J=18 and 7 Hz, 1H), 3.02-2.70 (m, 4H), 2.10-2.0 (br, 1H), 1.50 (s, 9H), 1.41(s, 9H).

Step 5: Preparation of dihydro-5(S)-(4-(1,1-dimethylethoxycarbonylamino))-2(S)-N-(t-butylcarboxamido)-piperazinylmethyl)-3(R)-phenylmethyl-3(2H)-furanone

To a solution of 22.40g (0.0662 mol) dihydro-5(S)-((trifluoromethanesulfonyl)oxymethyl)-3(R)-phenylmethyl-3(2H)-furanone (prep in step 1) and 18.0g (0.063mol) of n-t-butyl-4-(1,1-dimethylethoxycarbonylamino)piperazine-2(S)-carboxamide dissolved in 180 mL of isopropanol was added 11.53 mL (0.0662 mol) of N,N-diisopropylethylamine. After 2.5 hours another 1.2g of dihydro-5(S)-((trifluoromethanesulfonyl)oxymethyl)-3(R)-phenylmethyl-3(2H)-furanone was added. The reaction was complete by thin layer chromatography (tlc) after 3.5 hours and was concentrated to a thick oil. Trituration with EtOAc:hexanes (1:2, 200mL) provided a white solid which was filter d and discarded. The oil was purified by flash column

- 92 -

chromatography (120 x 150 mm column, EtOAc:hexanes gradient elution 1:1, 2:1, 3:1 to all EtOAc) to afford the title compound.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34-7.17 (m, 5H), 6.31 (br s, 1H), 4.38 (br m, 1H), 3.96-3.92 (m, 1H), 3.79 (br m, 1H), 3.16 (dd, J=13.6 and 4.4 Hz, 1H), 3.08-2.99 (m, 3H), 2.90-2.82 (m, 1H), 2.80 (dd, J=13.5 and 8.9 Hz, 1H), 2.78 (m, 1H), 2.67-2.61 (m, 1H), 2.58-2.49 (m, 1H), 2.38-2.32 (m, 1H), 2.32-2.04 (m, 1H), 1.99-1.92 (m, 1H), 1.45 (s, 9H), 1.29 (s, 9H).

Step 6: Preparation of 2(R)-phenylmethyl-4(S)-(t-butyldimethylsilyloxy)-5-(1-(4-(1,1-dimethylethoxycarbonylamino)))-2(S)-N-(t-butylcarboxamido)-piperazinyl)-pentaneamide

To 25.50g (52.50 mmol) of dihydro-5(S)-(4-(1,1-dimethylethoxycarbonylamino))-2(S)-N-(t-butylcarboxamido)-piperazinyl)methyl)-3(R)-phenylmethyl-3(2H)-furanone dissolved in 120 mL DME cooled to 0°C was added a solution of 60 mL of water and 1.512g (63.01 mmol) of lithium hydroxide. After 0.5 hours the reaction was quenched with the addition of 10% HCl until pH 6 and the solution was concentrated in vacuo. The residue was dissolved in 50 mL water and extracted with EtOAc (4 x 75 mL) and the organic layers were washed with water (1 x 20 mL), brine (1 x 20 mL). The aqueous was back extracted with EtOAc (2 x 75 mL) and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated to provide a yellow solid. This crude product was dissolved in 100 mL of DMF and 17.87g (0.262 mol) of imidazole was added, cooled to 0°C and then 31.50g (0.21 mol) of t-butyldimethylsilyl chloride was added. This stirred 1 hour at 0°C and was then

- 93 -

warmed to room temperature. After 20 hours the reaction was quenched with 10 mL methanol and concentrated to half the volume. 100 mL of pH 7 buffered water was added and the aqueous was extracted with EtOAc (4 x 100 mL), the combined organic layers were washed with 10% HCl (2 x 50 mL), water (3 x 75 mL), and brine (1 x 50 mL), dried over MgSO<sub>4</sub> and concentrated to obtain the title compound. This material was used directly in the next step.

Step 7: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-(t-butyldimethylsilyloxy)-5-(1-(4-(1,1-dimethylethoxycarbonylamino)))2(S)-N-(t-butylcarboxamido)-piperazinyl)-pentaneamide

To 27.0g (0.0446mol) of the crude material from step 6 dissolved in 180 mL of DMF and cooled to 0°C was added 8.98g (0.0468 mol) of EDC, 6.32g (0.0468 mol) of HOBt, and 7.31g (0.049 mol) aminohydroxy indane. Triethylamine (6.52 mL, 0.0468 mol) was added and the reaction stirred at 0°C for 2 hours, room temperature for 16 hours and was quenched by diluting with 500 mL of EtOAc. The organic layer was washed with 10% HCl (2 x 100 mL), saturated NaHCO<sub>3</sub> (1 x 100 mL), water (3 x 150 mL), brine (1 x 75 mL), dried over MgSO<sub>4</sub> and concentrated to yield the title compound as a white foam.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.4-7.17 (m, 9H), 6.51 (br s, 1H), 5.79 (br s, 1H), 5.23 (m, 1H), 4.23 (br s, 1H), 4.06 (m, 1H), 3.96-3.84 (m, 2H), 3.07-2.78 (m, 8H), 3.65 (dd, J=9.6 and 4.1 Hz, 1H), 2.56-2.44 (m, 2H), 2.29 (dd, J=12.0 and 4.5 Hz, 1H), 2.17-2.09 (m, 1H), 1.79 (br s, 1H), 1.44 (s, 9H), 1.35 (s, 9H), 1.10 (s, 1H), 0.84 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H).

- 94 -

Step 8: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-(hydroxy)-5-(1-(4-(1,1-dimethylethoxycarbonylamino)))  
2(S)-N-(t-butylcarboxamido)-piperazinyl)-  
pentaneamide

5 To 32.20g (0.0437 mol) of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-(t-butyl-  
dimethylsilyloxy)-5-(1-(4-(1,1-dimethylethoxycarbonylamino)))  
2(S)-N-(t-butylcarboxamido)-piperazinyl)-pentane-  
10 amide was added 437 mL (0.437 mol) of tetrabutyl-  
ammonium fluoride (1.0M solution in THF, Aldrich). The  
reaction stirred for 18 hours and was then concentrated  
to 200 mL and diluted with 700 mL of EtOAc. This was  
washed with water (2 x 100 mL), brine (1 x 50 mL) and  
15 the aqueous layers were back extracted with EtOAc (2 x  
200 mL). The combined organic layers were dried over  
MgSO<sub>4</sub> and concentrated to an oil. Purification via  
flash column chromatography (120 x 150 mm column,  
gradient elution CH<sub>2</sub>Cl<sub>2</sub>: CHCl<sub>3</sub>/saturated with NH<sub>3</sub>:  
20 methanol, increasing methanol from 1%, 1.5%, 2%)  
afforded the title compound as a white foam.  
1H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31-7.11 (m, 9H), 6.41 (br  
s, 1H), 6.23 (d, J=8.6 Hz, 1H), 5.25 (dd, J=8.6 and  
4.7Hz, 1H), 4.21 (m, 1H), 3.83-3.82 (m, 2H), 3.78-3.61  
25 (m, 2H), 3.22-3.19 (m, 2H), 3.03-2.78 (m, 8H),  
2.62-2.58 (m, 1H), 2.41-2.35 (m, 2H), 2.04-2.02 (m,  
1H), 1.57-1.50 (m, 1H), 1.45 (s, 9H), 1.32 (s, 9H).

30.

- 95 -

Step 9: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-(hydroxy)-5-(1-(2(S)-N-(t-butylcarboxamido)-piperazinyl)-pentane-  
amide

5 To 21.15g (0.034 mol) of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-(hydroxy)-5-(1-(4-(1,1-dimethylethoxycarbonylamino)))-2(S)-N-(t-butylcarboxamido)-piperazinyl)-pentaneamide dissolved in 350 mL of methylene chloride and cooled to 0°C was  
10 added 22.43 mL (0.204 mol) 2,6-lutidine and then 32.85 mL (0.170 mol) of trimethylsilyltriflate over 5 minutes. After 0.5 hours the reaction was quenched with 10% HCl (80 mL) and this stirred 0.5 hours. To  
15 this was added 100 mL of saturated NaHCO<sub>3</sub> and then solid NaHCO<sub>3</sub> until pH 8. The aqueous layer was then extracted with EtOAc (4 x 100 mL) and the combined organic layers were washed with water (1 x 50 mL), brine (1 x 75 mL), dried over MgSO<sub>4</sub> and concentrated. The residue was purified via column chromatography (120  
20 x 150 mm column, gradient elution CH<sub>2</sub>Cl<sub>2</sub>:CHCl<sub>3</sub> saturated with NH<sub>3</sub>: MeOH, slowly increasing methanol 2%, 3%, 4%, 5%, 6%, to 10%). This provided the title product as a white foam.  
25 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53 (s, 1H), 7.29-7.09 (m, 9H), 6.52 (d, J=8.3 Hz, 1H), 5.24 (dd, J=8.2 and 4.9 Hz, 1H), 4.23 (dd, J=4.7 and 4.03 Hz, 1H), 4.25-4.00 (br s, 1H), 3.83-3.81 (m, 1H), 3.03-2.88 (m, 4H), 2.82-2.73 (m, 7H), 2.50-1.60 (br s, 2H), 2.45 (d, J=6.2 Hz, 2H), 2.32-2.29 (m, 1H), 1.98 (m, 1H), 1.51 (m, 1H),  
30 1.33 (s, 9H).



- 96 -

Step 10: Preparation of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide

5 To 10.0g (0.019 mol) of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(2(S)-N-(t-butylcarboxamido)-piperazinyl))-pentaneamide and 3.45g (0.021 mol) of 3-picolyl chloride dissolved in 40 mL of DMF was added 5.85 mL (0.042 mol) of  
10 triethylamine. After 3 hours an additional 0.313g of 3-picolyl chloride was added. After an additional 2 hours the reaction was diluted with 400 mL of EtOAc and washed with water (3 x 75 mL), brine (1 x 100 mL),  
15 dried over MgSO<sub>4</sub> and concentrated. The residue was triturated with 30 mL of EtOAc and the resulting white precipitate was collected. Further recrystallization from EtOAc provided the title product (mp 167.5-168°C).



#### EXAMPLE 16

20







Employing substantially the same procedure as described in Example 15, but treating the N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentane-  
25 amide used therein (compound (i) below) with the alkylating agent (ii) indicated below in place of the 3-picolyl chloride used in Step 10 therein, the following products defined by formula (iii) were made:

30









- 97 -








- 98 -

	<u>R<sup>1</sup></u>	<u>X</u>
5	<chem>CH3CH2-</chem>	I
		Br
10		Cl
15		Cl
20		Cl
25		I
30		Cl

- 99 -

	<u>R<sup>1</sup></u>	<u>X</u>
5		Cl
		I
10		Cl
		Cl
15		Cl
20	$\text{CH}_3\text{O}(\text{CH}_2\text{CH}_2\text{O})_2\text{-CH}_2\text{CH}_2\text{-}$	I
		I
25		I
30		Cl

- 100 -

	<u>R<sup>1</sup></u>	<u>X</u>
5		I
10		Cl
15		Cl
20		Cl
25		Cl

EXAMPLE 17

Preparation of dihydro-5(S)-(tert-butyldimethylsilyl-oxymethyl)-3(2H)-furanone

30 To a solution of 3.00g (25.8 mmol) of dihydro-5(S)-(hydroxymethyl)-2(3H)-furanone dissolved in 25 mL of dichloromethane was added 3.51g (51.6 mmol) of imidazole and then 4.67g (31.0 mmol) of tert-butyl-

- 101 -

dimethylsilyl chloride. The reaction stirred at room temperature for 8 hours and was quenched with 2 mL of methanol. The mixture was concentrated to an oil and then diluted with 150 mL of ether and washed with 5% HCl (2 x 10 mL), saturated NaHCO<sub>3</sub> (1 x 10 mL), water (1 x 10 mL), and brine (1 x 10 mL), dried over MgSO<sub>4</sub> and concentrated. The residue was purified by flash chromatography (40 x 150 mm column, gradient elution, hexanes:ethyl/acetate 5:1 to 4:1) to afford the product as a clear oil.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.68-4.60 (m, 1H), 3.89 (dd, J=3.3 and 11.3 Hz, 1H), 3.71 (dd, J=3.2 and 5411.3 Hz, 1H), 2.71-2.45 (m, 2H), 2.35-2.16 (m, 2H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H).

15

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations, or modifications, as come within the scope of the following claims and its equivalents.


25

30

- 102 -

WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein

X is -OH or -NH<sub>2</sub>;

Z is -O, -S, or -NH;

15 R is hydrogen or C<sub>1-4</sub> alkyl;

$R^1$  and  $R^2$  are independently:

- 1) hydrogen,
- 2)  $-C_{1-4}$  alkyl unsubstituted or substituted with one or more of
  - a) halo,
  - b) hydroxy,
  - c)  $C_{1-3}$  alkoxy,
  - d) aryl unsubstituted or substituted with one or more of  $C_{1-4}$ alkyl, hydroxy or aryl,
  - e)  $-W$ -aryl or  $-W$ -benzyl, wherein W is  $-O-$ ,  $-S-$ , or  $-NH-$ ,
  - f) a 5-7 membered cycloalkyl group unsubstituted or substituted with one or more of

- 103 -

- 5
- i) halo,
  - ii) hydroxy,
  - iii) C<sub>1-3</sub> alkoxy, or
  - iv) aryl,
- g) heterocycle unsubstituted or substituted with one or more of hydroxy, C<sub>1-4</sub>alkyl optionally substituted with hydroxy, or Boc,
- 10
- h)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
  - i)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
  - j)  $\text{-NH-SO}_2\text{C}_{1-3}\text{alkyl}$ ,
  - k)  $\text{-NR}_2$ ,
- 15
- l)  $\text{-COOR}$ , or
  - m)  $\text{-((CH}_2\text{)}_m\text{O)}_n\text{R}$  wherein m is 2-5 and n is zero, 1, 2 or 3, or
- 3) aryl, unsubstituted or substituted with one or more of
- 20
- a) halo,
  - b) hydroxy,
  - c)  $\text{-NO}_2$  or  $\text{-NR}_2$ ,
  - d) C<sub>1-4</sub>alkyl,
  - e) C<sub>1-3</sub> alkoxy, unsubstituted or
- 25
- substituted with one or more of  $\text{-OH}$  or C<sub>1-3</sub> alkoxy,
  - f)  $\text{-COOR}$ ,
  - g)  $\text{-C(=O)NR}_2$ ,
- 30
- h)  $\text{-CH}_2\text{NR}_2$ ,



- 104 -

- 5
- i)  $-\text{CH}_2\overset{\text{O}}{\parallel}\text{NHC}R$ ,
  - j)  $-\text{CN}$ ,
  - k)  $-\text{CF}_3$ ,
  - l)  $-\overset{\text{O}}{\parallel}\text{NHC}R$ ,
  - m) aryl  $\text{C}_{1-3}$  alkoxy,
  - n) aryl,
  - o)  $-\text{NRSO}_2R$ ,
  - 10 p)  $-\text{OP}(O)(\text{OR}_x)_2$ , or
  - q)  $-\text{R}^5$ , as defined below; or

15  $\text{R}^1$  and  $\text{R}^2$  can be joined together to form with the nitrogen to which  $\text{R}^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which consists of the nitrogen to which  $\text{R}^1$  is attached and from 2 to 9 carbon atoms, and is unsubstituted or substituted with

- 20
- 1) hydroxy,
  - 2)  $\text{C}_{1-4}$  alkyl unsubstituted or substituted with one or more of
    - a) halo,
    - b) hydroxy,
    - c)  $\text{C}_{1-3}$  alkoxy,
    - 25 d) aryl,
    - e) a 5-7 membered cycloalkyl group unsubstituted or substituted with one or more of
      - i) halo,
      - 30 ii) hydroxy,
      - iii)  $\text{C}_{1-3}$  alkoxy, or
      - iv) aryl,
      - f) heterocycle, or
      - g)  $-\text{NR}_2$ .

- 105 -

- 3)  $C_{1-3}$  alkoxy,
- 4)  $-NH-\overset{\overset{O}{\parallel}}{C}OC_{1-3}alkyl,$
- 5)  $-NH-\overset{\overset{O}{\parallel}}{C}-C_{1-3}alkyl,$
- 6)  $-NH-SO_2C_{1-3}alkyl,$
- 7) heterocycle,
- 8)  $-W-aryl,$  or
- 9)  $-W-\overset{\overset{O}{\parallel}}{C}-aryl,$

wherein W is defined above; or

$R^1$  and  $R^2$  can be joined together to form with the nitrogen to which  $R^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which consists of the nitrogen to which  $R^1$  is attached, from 1 to 8 carbon atoms and one or more unsubstituted or substituted heteroatom selected from

- 1)  $-N-\overset{\overset{V}{|}}{R^1},$

wherein V is absent or  $-\overset{\overset{O}{\parallel}}{C}-Q-$  or  $-SO_2-Q-$ ,  $R^1$  is defined as above for when  $R^1$  is independent from and not joined to  $R^2$ , and wherein Q is absent or  $-O-$ ,  $-NR-$ , or heterocycle optionally substituted with  $-C_{1-4}alkyl,$

- 2)  $-N-\overset{\overset{heterocycle}{|}}{R^1},$
- 3)  $-N-\overset{\overset{C_{1-4}alkenyl}{|}}{R^1},$  unsubstituted or substituted with aryl,

- 106 -

- 4)  $\begin{array}{c} \text{-N-} \\ | \\ \text{SO}_2\text{-C}_{1-4}\text{alkenyl, unsubstituted or} \\ \text{substituted with aryl,} \end{array}$
- 5)  $\text{-S(O)}_p\text{-}$ ,  
wherein p is zero, 1 or 2, or
- 6)  $\text{-O-}$ ; or

$R^1$  and  $R^2$  can be joined together to form with the nitrogen to which  $R^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system, which consists of the nitrogen to which  $R^1$  is attached and from 2 to 9 carbon atoms, in which the saturated ring system is fused to a phenyl ring and the phenyl ring is unsubstituted or substituted with one or more of

- 1) halo,
- 2)  $\text{C}_{1-3}$  alkoxy,
- 3) hydroxy,
- 4)  $\text{C}_{1-4}$  alkyl,
- 5)  $\text{-NHR}^1$ ,
- wherein  $R^1$  is defined as above for when  $R^1$  is independent from and not joined to  $R^2$ , or
- 6)  $\text{-NH-heterocycle}$ ;

$R^3$  is

- 1)  $\text{-(CH}_2\text{)}_r\text{-R}^4$ ,  
wherein r is zero through 5,
- 2)  $\text{C}_{1-4}\text{alkenyl-R}^4$ , or
- 3)  $\text{C}_{1-4}\text{alkynyl-R}^4$ ;

$R^4$  is

- 1) hydrogen,
- 2)  $\text{C}_{1-4}$  alkyl,

- 107 -

- 3) C<sub>5</sub>-C<sub>10</sub> cycloalkyl, optionally substituted with hydroxy,
- 4) C<sub>6</sub>-C<sub>10</sub> aryl, unsubstituted or substituted with one or more of
- 5 a) halo,
- b) hydroxy,
- c) -NO<sub>2</sub> or -NR<sub>2</sub>,
- d) C<sub>1-4</sub>alkyl,
- 10 e) C<sub>1-3</sub> alkoxy, unsubstituted or substituted with one or more of -OH or C<sub>1-3</sub> alkoxy,
- f) -COOR,
- g)  $\begin{array}{c} \text{-CNR}_2 \\ || \\ \text{O} \end{array}$ ,
- 15 h) -CH<sub>2</sub>NR<sub>2</sub>,
- i)  $\begin{array}{c} \text{-CH}_2\text{NHCR} \\ || \\ \text{O} \end{array}$ ,
- j) -CN,
- k) -CF<sub>3</sub>,
- 20 l)  $\begin{array}{c} \text{-NHCR} \\ || \\ \text{O} \end{array}$ ,
- m) aryl C<sub>1-3</sub> alkoxy,
- n) aryl,
- o) -NRSO<sub>2</sub>R,
- 25 p) -OP(O)(OR<sub>x</sub>)<sub>2</sub>, or
- q) -R<sup>5</sup>, as defined below, or
- 5) monocyclic or bicyclic heterocycle containing from 1 to 3 heteroatoms chosen from the group consisting of N, O, and S and which is
- 30 unsubstituted or substituted with R<sup>5</sup> and optionally with one or more of
- a) halo,
- b) C<sub>1-4</sub> alkyl, or
- c) C<sub>1-3</sub> alkoxy;

- 108 -

$R_x$  is H or aryl;

$R^5$  is

1)  $-W-(CH_2)_m-NR^6R^7$

5        wherein W is as defined above,  
         m is 2-5, and  
          $R^6$  and  $R^7$  are independently

a) hydrogen,

10        b)  $C_{1-6}$  alkyl, unsubstituted or substituted  
         with one or more of

         i)  $C_{1-3}$  alkoxy,

         ii)  $-OH$ , or

         iii)  $-NR_2$ ,

15        c) the same or different and joined  
         together to form a 5-7 member  
         heterocycle, such as morpholino,  
         containing up to two additional  
         heteroatoms selected from

20         $\begin{array}{c} R \\ | \\ -N- \end{array}$ ,  $-O-$ ,  $\begin{array}{c} O \\ || \\ -S- \end{array}$ ,  $-S-$ , or  $-SO_2-$ , the  
         heterocycle optionally substituted with  
          $C_{1-4}$  alkyl, or

d) aromatic heterocycle unsubstituted or  
substituted with one or more of


25        i)  $C_{1-4}$  alkyl, or

         ii)  $-NR_2$ ,

30        2)  $-(CH_2)_q-NR^6R^7$  wherein q is 1-5, and  $R^6$  and  $R^7$   
         are defined above, except that  $R^6$  or  $R^7$  are  
         not H or unsubstituted  $C_{1-6}$  alkyl, or

3) benzofuryl, indolyl, azacycloalkyl,  
azabicyclo  $C_{7-11}$  cycloalkyl, or  
benzopiperidinyll, unsubstituted or  
substituted with  $C_{1-4}$  alkyl;

- 109 -



5

wherein  $\text{R}^8$  is

- 1)  $-\text{CH}(\text{CH}_3)_2$ ,
- 2)  $-\text{CH}(\text{CH}_3)(\text{CH}_2\text{CH}_3)$ , or
- 3) -phenyl;

10  $\text{J}^1$  and  $\text{J}^2$  are independently1)  $-\text{YR}^9$  wherein $\text{Y}$  is  $-\text{O}-$  or  $-\text{NH}-$ , and $\text{R}^9$  is

15

- a) hydrogen,
- b)  $\text{C}_{1-6}$  alkyl, unsubstituted or substituted with one or more of
  - i)  $-\text{NR}_2$ ,
  - ii)  $-\text{OR}$ ,
  - iii)  $-\text{NHSO}_2\text{C}_{1-4}$  alkyl,
  - iv)  $-\text{NHSO}_2$  aryl, or  $-\text{NHSO}_2(\text{dialkylaminoaryl})$ ,
  - v)  $-\text{CH}_2\text{OR}$ ,
  - vi)  $-\text{C}_{1-4}$  alkyl,

20

vii)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{COR} \end{array}$ ,

25

viii)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{CNR}_2 \end{array}$ ,

ix)  $\begin{array}{c} \text{NH} \quad \text{NR}_2 \\ \diagup \quad \diagdown \\ \text{C} \\ \parallel \\ \text{NH} \end{array}$  or  $\begin{array}{c} \text{NH} \quad \text{NR}_2 \\ \diagup \quad \diagdown \\ \text{C} \\ \parallel \\ \text{N-CN} \end{array}$



30

x)  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{NHC} \end{array} \text{R}^{13}$ , wherein  $\text{R}^{13}$  is

- 110 -

- 5
- A) -H,  
 B) -C<sub>1-4</sub> alkyl,  
 C) -aryl,  
 D) -heterocycle, or  
 E) -NH-, -O- or -(CH<sub>2</sub>)<sub>n</sub>-  
 wherein n is zero, 1, 2 or 3,  
 substituted with
- 10
- I) -C<sub>1-4</sub> alkyl,  
 unsubstituted or  
 substituted with one or  
 more of aryl or  
 heterocycle, or  
 II) aryl, unsubstituted or  
 substituted with  
 15 heterocycle,
- xi) -NR<sub>3</sub><sup>⊕</sup> A<sup>⊖</sup> wherein A<sup>⊖</sup> is a  
 counterion,  
 xii) -NR<sup>10</sup>R<sup>11</sup> wherein R<sup>10</sup> and R<sup>11</sup> are  
 20 the same or different and are C<sub>1-5</sub>  
 alkyl joined together directly to  
 form a 5-7 membered heterocycle  
 containing up to one additional  
 heteroatom selected from -O-, -S-,  
 or -NR-,  
 25 xiii) -aryl,  
 xiv) -CHO,  
 xv) -OP(O)(OR<sub>x</sub>)<sub>2</sub>,  
 xvi) -O-C(=O)-C<sub>1-4</sub>alkyl substituted with  
 30 one or more of amine or quaternary  
 amine, or -O-((CH<sub>2</sub>)<sub>m</sub>O)<sub>n</sub>-R, or  
 -OP(O)(OR<sub>x</sub>)<sub>2</sub>.

- 111 -




5

c)  $-\text{((CH}_2\text{)}_m\text{O)}_n\text{CH}_3$  or  $-\text{((CH}_2\text{)}_m\text{O)}_n\text{H}$ ,  
wherein m and n are defined above,

2)  $-\text{N(R}^9\text{)}_2$ ,

3)  $-\text{NR}^{10}\text{R}^{11}$  wherein  $\text{R}^{10}$  and  $\text{R}^{11}$  are defined  
above, or

10



15

wherein Y,  $\text{R}^9$  and n are defined above; and

$\text{R}^{12}$  is

1) hydrogen,

20




2) aryl, unsubstituted or substituted with one  
or more of

a)  $\text{R}^{14}$ , wherein  $\text{R}^{14}$  is


i) halo,

ii)  $-\text{OR}$ ,

25



30



viii)  $-\text{C}_{1-4}$  alkyl,

ix) phenyl



- 112 -

x)  $-\text{CF}_3$ ,xi)  $-\overset{\text{R}}{\underset{|}{\text{N}}}-\text{SO}_2\text{R}$ ,xii)  $-\text{OP}(\text{O})(\text{OR}_x)_2$ , orxiii)  $-\overset{\text{O}}{\underset{||}{\text{C}}}\text{OR}$ ,b)  $-\text{C}_{1-4}$  alkyl- $\text{NR}_2$ , orc)  $-\text{O}-\overset{\text{O}}{\underset{||}{\text{C}}}-\text{C}_{1-4}$  alkyl substituted with  
one or more of amine or quaternary  
amine or  $-\text{OP}(\text{O})(\text{OR}_x)_2$ ,3) heterocycle, the ring or rings being  
unsubstituted or substituted with one or more  
ofa)  $\text{R}^{14}$ , as defined above,b)  $-\text{OC}_{1-4}$  alkenyl,c) phenyl- $\text{C}_{1-4}$  alkyl,d)  $-\text{O}-\overset{\text{O}}{\underset{||}{\text{C}}}-\text{C}_{1-4}$  alkyl substituted with  
one or more of amine or quaternary  
amine, or  $-\text{OP}(\text{O})(\text{OR}_x)_2$ , or  
 $-\text{O}((\text{CH}_2)_m\text{O})_n-\text{R}$ , ore)  $-\text{O}-\overset{\text{O}}{\underset{||}{\text{C}}}-\text{O}-((\text{CH}_2)_m\text{O})_n-\text{R}$ , or4) A 5 to 7 membered carbocyclic or 7-10  
membered bicyclic carbocyclic ring, the  
carbocyclic ring being unsubstituted or  
substituted with one or more ofa)  $\text{R}^{14}$ , as defined above,b)  $-\text{CH}_2\text{OR}$ ,

- 113 -

- c)  $-(\text{CH}_2)_n\text{-NR}_2$ ,  $\text{C}_{5-16}$ alkyl, pyridine,  
 $-(\text{CH}_2)_n\text{NR}-(\text{CH}_2)_n\text{-NR}_2$ ,  $-(\text{CH}_2)_n\text{-}\overset{\text{O}}{\parallel}\text{C-OR}$ ,  
 $-((\text{CH}_2)_m\text{O})_n\text{-R}$ , quinuclidiniumyl  
5 substituted with R, piperazine-  
 $\text{C}_{1-4}$ alkyl-benzyl substituted once or  
more with R, or  
morpholino- $\text{C}_{1-4}$ alkyl-benzyl,  
10 d)  $-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{C}_{1-4}$ alkyl substituted with  
one or more of amine or quaternary  
amine,  $-\text{OP}(\text{O})(\text{OR}_x)_2$ , or  
 $-\text{O}-((\text{CH}_2)_m\text{O})_n\text{-R}$ ,  
15 e)  $-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-((\text{CH}_2)_m\text{O})_n\text{-R}$ , or  
f)  $-\text{C}_{1-4}$ alkyl-phenyl;

or a pharmaceutically acceptable salt thereof.

- 20 2. A compound according to Claim 1 wherein:

$\text{R}^1$  and  $\text{R}^2$  are joined together to form with the nitrogen  
to which  $\text{R}^1$  is attached a 3 to 10 membered monocyclic  
or bicyclic saturated ring system which consists of the  
25 nitrogen to which  $\text{R}^1$  is attached and from 2 to 9 carbon  
atoms, and is unsubstituted or substituted with

- 1) hydroxy,  
2)  $\text{C}_{1-4}$  alkyl unsubstituted or substituted with  
one or more of  
30 a) hydroxy,  
b)  $\text{C}_{1-3}$  alkoxy,  
c) aryl,

- 114 -

- d) a 5-7 membered cycloalkyl group  
unsubstituted or substituted with one or  
more of
- i) halo,
  - ii) hydroxy,
  - iii) C<sub>1-3</sub> alkoxy, or
  - iv) aryl,
- e) heterocycle, or
- f) -NR<sub>2</sub>,
- 3) C<sub>1-3</sub> alkoxy,
- 4)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- 5)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,
- 6)  $\text{-NH-SO}_2\text{C}_{1-3}\text{alkyl}$ ,
- 7) -W-aryl, or
- 8)  $\text{-W-C(=O)aryl}$ ,

wherein W is -O-, -S-, or -NH-; or

R<sup>1</sup> and R<sup>2</sup> are joined together to form with the nitrogen  
to which R<sup>1</sup> is attached a 3 to 10 membered monocyclic  
or bicyclic saturated ring system which consists of the  
nitrogen to which R<sup>1</sup> is attached, from 1 to 8 carbon  
atoms and one or more unsubstituted or substituted  
heteroatom selected from

- 1)  $\text{-N-}$   
|  
V-R<sup>1</sup>,

wherein V is absent or  $\text{-C(=O)-}$  or  $\text{-SO}_2\text{-}$ ,  
R<sup>1</sup> is defined as above for when R<sup>1</sup> is  
independent from and not joined to R<sup>2</sup>,  
and wherein Q is absent or -O-, -NR-, or

- 115 -

heterocycle optionally substituted with  
-C<sub>1-4</sub>alkyl,

- 2) -N-  
|  
C<sub>1-4</sub> alkenyl, unsubstituted or substituted  
with aryl,  
3) -S(O)<sub>p</sub>-,  
wherein p is zero, 1 or 2, or  
4) -O-; or

10 R<sup>1</sup> and R<sup>2</sup> are joined together to form with the nitrogen  
to which R<sup>1</sup> is attached a 3 to 10 membered monocyclic  
or bicyclic saturated ring system, which consists of  
the nitrogen to which R<sup>1</sup> is attached and from 2 to 9  
carbon atoms, in which the saturated ring system is  
15 fused to a phenyl ring and the phenyl ring is  
unsubstituted or substituted with one or more of

- 1) C<sub>1-3</sub> alkoxy,  
2) hydroxy,  
3) C<sub>1-4</sub> alkyl, or  
20 4) -NHR<sup>1</sup>,

wherein R<sup>1</sup> is defined as above for when R<sup>1</sup>  
is independent from and not joined to R<sup>2</sup>.

3. A compound according to Claim 2 wherein:

25 R<sup>1</sup> and R<sup>2</sup> are joined together to form with the nitrogen  
to which R<sup>1</sup> is attached a 3 to 10 membered monocyclic  
or bicyclic saturated ring system which consists of the  
nitrogen to which R<sup>1</sup> is attached and from 2 to 9 carbon  
30 atoms, and is unsubstituted or substituted with

- 1) hydroxy,  
2) C<sub>1-4</sub> alkyl unsubstituted or substituted with  
one or more of

- 116 -

- 5 a) hydroxy,  
 b) C<sub>1-3</sub> alkoxy,  
 c) aryl,  
 d) a 5-7 membered cycloalkyl group  
 unsubstituted or substituted with one or  
 more of  
 i) halo,  
 ii) hydroxy,  
 iii) C<sub>1-3</sub> alkoxy, or  
 10 iv) aryl,  
 e) heterocycle, or  
 f) -NR<sub>2</sub>,  
 3) C<sub>1-3</sub> alkoxy,  
 15 4)  $\text{-NH-C(=O)C}_{1-3}\text{alkyl}$ ,  
 5)  $\text{-NH-C(=O)-C}_{1-3}\text{alkyl}$ ,  
 6)  $\text{-NH-SO}_2\text{C}_{1-3}\text{alkyl}$ ,  
 7) -W-aryl, or  
 20 8)  $\text{-W-C(=O)-aryl}$ ,

wherein W is -O-, -S-, or -NH-; or

25 R<sup>1</sup> and R<sup>2</sup> are joined together to form with the nitrogen  
 to which R<sup>1</sup> is attached a 3 to 10 membered monocyclic  
 or bicyclic saturated ring system which consists of the  
 nitrogen to which R<sup>1</sup> is attached, from 1 to 8 carbon  
 atoms and one or more unsubstituted or substituted  
 heteroatom selected from

- 30 1)  $\begin{array}{c} \text{-N-} \\ | \\ \text{V-R}^1 \end{array}$ ,

wherein V is absent or  $\text{-C(=O)-}$  or  $\text{-SO}_2\text{-}$ ,

- 117 -

$R^1$  is defined as above for when  $R^1$  is independent from and not joined to  $R^2$ , and wherein Q is absent or -O-, -NR-, or heterocycle optionally substituted with

5

-C<sub>1-4</sub>alkyl,

2) -S(O)<sub>p</sub>-,

wherein p is zero, 1 or 2, or

3) -O-;

10  $R^3$  is benzyl, unsubstituted or substituted with one or more of

a) hydroxy,

b) -NO<sub>2</sub>, or -NR<sub>2</sub>,

c) C<sub>1-4</sub>alkyl,

15

d) C<sub>1-3</sub> alkoxy, unsubstituted or substituted with one or more of -OH or C<sub>1-3</sub> alkoxy,

e)  $\begin{array}{c} \text{CNR}_2 \\ || \\ \text{O} \end{array}$ ,

20

f) -CH<sub>2</sub>NR<sub>2</sub>,

g)  $\begin{array}{c} \text{O} \\ || \\ \text{CH}_2\text{NHC} \end{array}$ R,

h) -CF<sub>3</sub>,

25

i)  $\begin{array}{c} \text{O} \\ || \\ \text{NHC} \end{array}$ R,

j) -NRSO<sub>2</sub>R,

k) -OP(O)(OR<sub>x</sub>)<sub>2</sub>, or

l) -R<sup>5</sup>;

30 and B is absent.

- 118 -

4. A compound according to Claim 3 wherein:

X is -OH;

Z is -O;


5  $R^1$  and  $R^2$  are joined together to form with the nitrogen to which  $R^1$  is attached a 3 to 10 membered monocyclic or bicyclic saturated ring system which consists of the nitrogen to which  $R^1$  is attached and from 2 to 9 carbon atoms, and is unsubstituted or substituted with

10 -W-aryl or -W- $\overset{\text{O}}{\underset{\text{O}}{\text{C}}}$ -aryl; or

$R^1$  and  $R^2$  are joined together to form with the nitrogen to which  $R^1$  is attached a 3 to 10 membered monocyclic  
15 or bicyclic saturated ring system which consists of the nitrogen to which  $R^1$  is attached, from 1 to 8 carbon atoms and one of  $\begin{array}{c} \text{-N-} \\ | \\ \text{V-R}^1 \end{array}$ ,


20 wherein V is absent or  $\overset{\text{O}}{\underset{\text{O}}{\text{C}}}$ -Q- or -SO<sub>2</sub>-Q-,  
 $R^1$  is defined as above for when  $R^1$  is independent from and not joined to  $R^2$ ,  
and wherein Q is absent or -O-, -NR- or heterocycle optionally substituted with  
25 -C<sub>1-4</sub>alkyl;

$R^3$  is benzyl, unsubstituted or substituted with one or more of (1) hydroxy, (2) C<sub>1-3</sub> alkoxy substituted with  
30. one or more of -OH or (3)



- 119 -

J<sup>1</sup> is -NH-C<sub>1-4</sub>alkyl; and  
 J<sup>2</sup> is



10 5. The compound

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-  
 4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-  
 (4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide,

15

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-  
 4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-  
 butylcarboxamido)-piperazinyl))-pentaneamide,

20

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-  
 morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-  
 5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-  
 decahydroisoquinoline)yl)-pentaneamide,

25

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-(2-(4-  
 morpholinyl)ethoxy)phenyl)methyl)-4(S)-hydroxy-5-  
 (1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-  
 piperazinyl))-pentaneamide,

30

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-  
 ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(2-(3(S)-N'-(t-  
 butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)-  
 yl)-pentaneamide,



- 120 -

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-((4-((2-hydroxy)-ethoxy)phenyl)methyl)-4(S)-hydroxy-5-(1-(4-carbobenzyloxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,

5

N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(2-(3(S)-N'-(t-butylcarboxamido)-(4aS,8aS)-decahydroisoquinoline)yl)-pentaneamide,

10

N-(4(S)-3,4-dihydro-1H-2,2-dioxobenzothiopyranyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-carbobenzyl-oxy-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide,

15

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide, or

20 a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

25

7. The pharmaceutical composition of Claim 6 for use in the treatment of AIDS, in the prevention of infection by HIV, in the treatment of infection of HIV, or in the inhibition of HIV protease.

30

8. The use of a compound of Claim 1 for the preparation of a medicament useful for treating AIDS in a patient receiving AIDS therapy.

- 121 -

9. The use of a compound of Claim 1 for the preparation of a medicament useful for preventing infection by HIV in a patient.

5 10. The use of a compound of Claim 1 for treating infection by HIV in a patient receiving therapy for HIV infection.

10 11. The use of a compound of Claim 1 for the preparation of a medicament useful for inhibiting HIV protease in a patient receiving HIV protease therapy.

15

20

25

30

## INTERNATIONAL SEARCH REPORT

PCT/US 92/09444

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07D217/26; C07D241/04; C07D409/12; A61K31/47 A61K31/495		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C07D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	EP,A,0 432 695 (F. HOFFMANN-LA ROCHE AG) 19 June 1991 see page 7, line 40 - page 8, line 50; claims 1,6,8-10 ---	1-4,6-11
Y	EP,A,0 434 365 (MERCK AND CO.) 26 June 1991 see page 23, line 10 - page 34, line 30; claims 1,12-24 ---	1-4,6-11
Y	JOURNAL OF MEDICINAL CHEMISTRY vol. 34, no. 3, March 1991, WASHINGTON US pages 1228 - 1230 TERRY A. LYLE 'Benzocycloalkyl amines as novel c-termini for HIV protease inhibitors' see the whole document --- -/--	1-4,6-11
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
29 JANUARY 1993		- 8. 02. 93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		HENRY J.C.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
Y	SCIENCE vol. 248, 20 April 1990, LANCASTER, PA US pages 358 - 361 NOEL A. ROBERTS ET AL 'Rational design of peptide-based HIV proteinase inhibitors' see the whole document -----	1-4,6-11

# INTERNATIONAL SEARCH REPORT

I International application No.

PCT/US 92/09444

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
The formulation of claims 1-3 is so complicated because of the long lists of cascading substituents that it does not comply with Art. 6 PCT prescribing that claims shall be clear and concise. For these reasons the search has been limited to the examples (Claims searched incompletely: 1-3)
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9209444  
SA 66920

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 29/01/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0432695	19-06-91	AU-A- 6787690	13-06-91
		CN-A- 1052482	26-06-91
		GB-A- 2239016	19-06-91
		JP-A- 3255076	13-11-91
EP-A-0434365	26-06-91	AU-A- 6822990	27-06-91
		CA-A- 2032259	19-06-91
		CN-A- 1053607	07-08-91